

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Relationship between triglyceride glucose index and the incidence of nonalcoholic fatty liver in elderly: a cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-039804
Article Type:	Original research
Date Submitted by the Author:	14-May-2020
Complete List of Authors:	Chen, Huanan; Zhengzhou University, Department of Nutrition and Food Hygiene, College of Public Health Li, Sangsang; Xinyang Central Hospital, Medical record room Amoah, Adwoa Nyantakyiwaa ; Zhengzhou University, Department of Nutrition and Food Hygiene, College of Public Health Bo, Yacong; The Chinese University of Hong Kong, Jockey Club School of Public Health and Primary Care Chen, Xuejiao; Zhengzhou University, Department of Social Medicine, College of Public Health Shi, Zhan; Henan University of Traditional Chinese Medicine, Department of Pharmacy, Zhengzhou People's Hospital Wan, Guodong; Henan Province Health and Family Planning Commission, Health Commission of Xinzheng Huang, Jian; Henan Province Center for Disease Control and Prevention, Henan Province Center for Disease Control and Prevention shi, songhe; Zhengzhou University, Department of Epidemiology and Biostatistics Lyu, Qunjun ; Zhengzhou University, Department of Nutrition and Food Hygiene, College of Public Health; Zhengzhou University, Department of Nutrition, The First Affiliated Hospital of Zhengzhou University
Keywords:	Hepatobiliary disease < GASTROENTEROLOGY, Lipid disorders < DIABETES & ENDOCRINOLOGY, PUBLIC HEALTH

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Relationship between triglyceride glucose index and the incidence of nonalcoholic fatty liver in elderly: a cohort study

Chen Huanan¹, Li Sangsang², Amoah, Adwoa Nyantakyiwaa¹, Bo Yacong³ Chen Xuejiao⁴, Shi Zhan⁵, Wan Guodong⁶, Huang Jian⁷, Shi Songhe⁸, Lyu Qunjun^{1,9}.

1. Department of Nutrition and Food Hygiene, College of Public Health, Zhengzhou University, Zhengzhou, Henan, P.R. China.
2. Medical record room, Xinyang Central Hospital, Xinyang, Henan, P.R. China.
3. Jockey Club School of Public Health and Primary Care, the Chinese University of Hong Kong
4. Department of Social Medicine, College of Public Health, Zhengzhou University, Zhengzhou, Henan, P.R. China.
5. Department of Pharmacy, Zhengzhou People's Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, P.R. China.
6. Health Commission of Xinzheng, Henan Province Health and Family Planning Commission, Henan, P.R. China.
7. Central for Disease Control of Xinzheng, Henan Province Center for Disease Control and Prevention, Henan, P.R. China.
8. Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, P.R. China.
9. Department of Nutrition, The First Affiliated Hospital of Zhengzhou University, Henan, P.R. China

Corresponding Author:

Qunjun Lyu, PhD, Department of Nutrition and Food Hygiene, College of Public Health, Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, 100 Science Road, Zhengzhou, China. Phone: (0371) 67781923, email: lqjnutr@zzu.edu.cn.

Songhe Shi, PhD, Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, 100 Science Road, Zhengzhou, China. Phone:(0371)

67781254, email: zzussh@126.com.

Abstracts

Objective: Nonalcoholic fatty liver diseases (NAFLD) is being one of the major causes of liver-related disease. While the relationship between triglyceride glucose (TyG) and NAFLD in elderly is not reported yet. In this study, we aimed to investigate the role of TyG index for predicting the incidence of NAFLD in elderly.

Design and setting : This is a prospective cohort study in Henan, China, from 2011-2018

Participants and Methods : In total, 46693 elderly who participated in a routine physical examination programme from 2011 to 2018 were included in this study. TyG index was calculated as \ln [fasting triglyceride (mg/dl)×fasting plasma glucose (mg/dl)/2], while NAFLD was defined as hepatic steatosis after excluding other causes based on the results of abdominal ultrasonography; Cox regression model were performed to explore the relationship between TyG index and NAFLD; Mediate effect was used to analyze the role of the TyG index in WHtR and NAFLD.

Results: During the 149041.50 person-years follow-up, a total of 5660 NAFLD events occurred (3.80/100 pearson-years). After adjusting for potential confounder factors, quartiles 4 of TyG index significantly increased the risk of NAFLD compared with quartile 1 on NAFLD, the hazard ratios (HRs) and 95% confidence intervals (CI) were 1.314(1.234,1.457). In addition, TyG index played a partial mediating role in the relationship between WHtR and NAFLD, and indirect effect was 1.009(1.006,1.011).

Conclusion: Higher TyG index was associated with higher risk of NAFLD in the older, so TyG index may be a novel predictor for NAFLD, regular examination and evaluation of the TyG index might be useful for controlling the occurrence of NAFLD.

Key words: Nonalcoholic fatty liver disease; Triglyceride glucose index; Waist-to-height ratio; Mediation effect.

Strengths and limitations of this study :

Data for this cohort study were retrieved from a large regular physical examination in

1
2
3
4 Henan, China.

5 Restricted cubic spline and Mediation effect were used in this study, which can reflect
6 the relationship between TyG index and NAFLD more realistically
7

8 The sample size and statistical power were sufficient in this study.
9

10 The severity of disease in this cohort study was not available when data were retrieved.
11
12 Part of participants were excluded in this study because they did not have abdominal
13 ultrasound testing.
14
15

16 **Introduction**

17 Nonalcoholic fatty liver disease(NAFLD) encompasses a series of spectrum of liver
18 diseases, ranged from simple steatosis, nonalcoholic steatohepatitis, cirrhosis to
19 hepatocellular carcinoma[1]. With the change of lifestyle and increase of obesity,
20 NAFLD is exceeding viral hepatitis and becoming the most common chronic liver
21 diseases, about a quarter of common population were affected by NAFLD in the
22 world[2, 3]. NAFLD is being one of the major causes of liver-related disease such as
23 cirrhosis, hepatocellular carcinoma and liver transplantation. Moreover, NAFLD is also
24 associated with higher prevalence and incidence of cardiovascular disease such as
25 coronary, cerebrovascular and peripheral vascular disease [4, 5]. In the next decade,
26 NAFLD is expected to become the leading cause for liver transplantation in the United
27 States instead of hepatitis C[6].
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 The development of NAFLD is a complex process involving genetic and environmental
43 factors. As an organ of metabolism, the disorder of glucose and lipid metabolism plays
44 an important role in the progress of NAFLD[7]. Several studies found that IR could
45 increase the risk of NAFLD even without the existence of T2DM, and IR may be a start
46 factor of steatosis[7-10].Furthermore, as an early marker of IR, TyG has been proposed
47 to be an inexpensive and reliable surrogate to IR[11, 12].While researches about the
48 relationship between TyG index and the risk of NAFLD were still limited [9, 13].
49 What's more, as far as we know, the association between TyG index and the incidence
50 of NAFLD in the older has not been reported.
51
52
53
54
55
56
57
58
59
60

1
2
3
4 WHtR is a maker of abdominal obesity, studies also found WHtR related to IR[14, 15]
5 as well as the higher risk of NAFLD [16-22]. Whether there is an existing effect of TyG
6 index on the relationship between WHtR and NAFLD and how it affects NAFLD is
7 still unclear. This retrospective cohort study was aimed to explore relationship between
8 baseline level of TyG index triglyceride glucose index and the incidence of NAFLD.
9
10
11
12

13 **1.Participants and methods**

14 **1.1 Subjects:**

15
16 We retrospectively analyzed the 99997 subjects who had the data of liver
17 ultrasonography, fasting triglyceride as well as fasting plasma glucose in physical
18 examination programme in Xinzheng, Henan Province, in Central China City from
19 January 2011 to December 2018. This physical examination programme was for the
20 local residents over 60 years old and was supported by the government of Xinzheng,
21 Henan Province in China. Individuals with the any of the following criteria were
22 excluded:1) missing follow-up; 2) subjects with NAFLD at baseline;3) subjects with
23 hepatitis B or C virus or had the history of excess alcohol intaking (the threshold for
24 women <20 g/ d and <30 g/d for men). A total of 46693 eligible participants were
25 included in this cohort study (**Figure 1**). The datasets generated and/or analysed during
26 the current study are available upon request. Given the retrospective nature of the
27 research, the requirement for informed consent was waived. Patients were not involved
28 in the recruitment and conduct of the study. The study protocol was approved by ethics
29 committee of Zhengzhou University in China.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 **Figure 1 Flow chart for participants exclusions performed**

52 **1.2 Data collection**

53 Demographic data and clinical information of the subjects were collected when they
54 underwent health check-up. Demographic data including age, sex, excess alcohol intake
55 (yes/no), current smoking status (yes/no), lives alone(yes/no), exercises
56 regularly(yes/no). The definition of current smoking was that subjects used to smoke
57
58
59
60

1
2
3
4 100 cigarettes or above in their lifetime, and now is still smoking regularly. Excessive
5 drinking was defined as that drinking more than 30g /d for men and 20g/d for women.
6
7 Exercise regularly was defined as more than 3 times a week, and 30 minutes moderate
8 intensity exercise each time. The clinic records including anthropometric measurements
9 (such as height, weight, blood pressure, waist circumference) and laboratory data.
10
11 Height measurement required the subjects without shoes, stand straight on the ground,
12 and their hips and heels against the wall, to measure the weight, the participants were
13 without shoes and wore light clothing. Blood pressure of the subjects in a sitting
14 position after 5 minutes of rest was measured twice by an electronic
15 sphygmomanometer (Omron HEM-7125, Kyoto, Japan), and the mean value of the two
16 measurements was recorded. Waist circumference was measured at the midpoint of the
17 distance between the lowest costal ridge and the upper border of the iliac crest. After
18 fasting for 8 hours, the blood samples of subjects were collected to detect the level of
19 fasting plasma glucose (FPG), total cholesterol (TC), and triglyceride (TG) by a
20 biochemical detector (DIRUI CS380, Changchun, China). Alanine aminotransferase
21 (ALT), aspartate transaminase (AST) and total bilirubin (TB) was detected by (DIRUI
22 CS380, Changchun, China). The TyG index were calculated as the \ln [fasting TG
23 (mg/dl) \times FPG (mg/dl)/2]. WHtR was defined waist circumference(cm)/height(cm).

38 **1.3 NAFLD definition**

39
40 All participants included underwent liver ultrasonography (SIUI CZXL-38G, Shantou,
41 China). The results of ultrasound prompted the existence of steatohepatitis: enhanced
42 liver echogenicity, echogenicity greater in liver than kidneys, deep attenuation and
43 vascular blurring[23], and after excluding the steatohepatitis caused by alcohol, viruses
44 and drugs was defined as NAFLD. All ultrasound examinations were performed by an
45 experienced professional radiologist.

52 **1.4 Statistics**

53 Categorical variables were showed as proportions while continuous variables were
54 presented as means \pm standard deviation (SD) or median (interquartile range) (IQR).
55 ANOVA analysis /two-paired sample t tests (continuous variables, normal distribution)
56
57
58
59
60

and chi-square tests (categorical variables) were used to compare the difference in different groups. Logistic regression for categorical variables and linear regression for continuous variables were used to obtain the *P* value for trend.

Cox regression models were used to explore the relationship between TyG index and the incidence of NAFLD, the lowest quartiles of TyG index was defined as the reference. Hazards ratio (*HR*) and confidence interval (*CI*) of NAFLD in quartiles and continuous were expressed in separate models. to assess the relationship across increasing quartiles, *P* value for trend tests were used by entering median value in each quartile in Cox regression models.

AUCs were used to evaluate the ability of baseline TyG index to predict the risk of NAFLD. Restricted cubic spline models were used to explore whether there was a nonlinear relationship between continuous and occurrence of NAFLD [24]. Mediation analysis used a Cox regression to study the mediate effect of TyG index between WHtR and NAFLD.

Mediation analysis was conducted using R version 3.5.0 (R Foundation for Statistical Computing, Vienna, Austria), and Restricted cubic spline were performed in Stata v 12.0 (Stata Corp, College Station, TX, USA). The other analyses were performed by SPSS software, version 21.0 (SPSS Inc, Chicago). Probability values for statistical tests, where two-tailed *P*-values<0.05 were regarded as significant.

2. Result

2.1 Baseline Characteristics of included subjects

A total of 46693 subjects were included in this study. The baseline characteristics of included participants based on follow-up were presented in **Table 1**. The mean age of subjects was 68.91 (7.17), and 48.89% were men. The average follow-up was 3.19(1.52) years, during the 149041 person-years follow-up, 5660 subjects occurred NAFLD (3.80/100 pearson-years). Subjects with NAFLD with higher BMI, WHtR, TC, FBG, DBP, SBP, ALT, and TB, and the incidence of NAFLD was higher in younger, current smoking, regular exercise, with diabetes, hypertension, while the baseline level of AST had no association with the incident of NAFLD.

Table 1 baseline characteristics of included subjects according to the follow-up outcome

variables	No NAFLD (n=41033)	NAFLD (n=5660)	P value
Men, n (%) †	20799(50.69)	2033(35.92)	<0.001
Age (years) ‡	69.18±7.27	66.93±6.00	<0.001
Current smoking, n (%) †	6846 (16.70)	594(10.51)	<0.001
Exercise, n (%) †	7865(19.22)	1131(20.02)	<0.001
Live alone, n (%) †	8772(21.38)	1015(17.93)	<0.001
Diabetes, n (%) †	5554(13.54)	1344(23.75)	<0.001
Hypertension, n (%) †	15945 (38.86)	2952(52.16)	<0.001
WHR‡	0.51±0.06	0.54±0.07	<0.001
BMI‡	23.62±2.85	26.02±3.10	<0.001
SBP (mmHg) ‡	132.62±19.38	135.32±19.76	<0.001
DBP (mmHg) ‡	78.92±10.34	80.91±10.33	<0.001
FPG (mmol/L) §	5.20(4.70-5.70)	5.30(4.80-5.93)	<0.001
TC (mmol/L) §	4.59(4.01-5.21)	4.69(4.09-5.38)	<0.001
TG (mmol/L) §	1.10(0.81-1.47)	1.28(0.90-1.77)	<0.001
TB (µmol/L) §	11.51(8.60-14.10)	11.30(8.30-13.80)	<0.001
ALT(U/L) §	18.00(13.00-24.50)	18.60(14.00-25.00)	<0.001
AST(U/L) §	21.80(16.89-26.90)	21.90(16.89-27.00)	0.892
TyG‡	8.43±0.54	8.61±0.59	<0.001

†: n (%); ‡: mean (SD); §: median (IQR)

Abbreviations: BMI, body mass index; WHtR, waist-to-height ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; TC, triglycerides; TG, triglyceride; TB, total bilirubin; ALT, alanine aminotransferase, AST, aspartate aminotransferase; TyG, triglyceride glucose.

2.2 Association between TyG index and NAFLD

The relationship between TyG index and the incidence of NAFLD were showed in **Table 2**. Compared with quartile 1 of TyG index, the hazard ratio (HR) and its corresponding 95% confidence interval (CI) for quartile2, quartile3, and quartile 4 were 1.056(0.971,1.149), 1.300(1.200,1.408) and 1.972(1.832,2.123), respectively, risk for NAFLD significantly higher with increasing quartiles of TyG for the *P* value of trend of linearity <0.001. What's more, even after adjusted possible confounding factors, the risk of quartile 3 of TyG index (1.314(1.234,1.457)) on the incident of NAFLD still existed. In order to further verify the relationship between the TyG index and the incidence of NAFLD, TyG index was used as continuous for the above analysis, the results also proved that higher level of TyG increased the risk of NAFLD

(1.265(1.200,1.334)), even after adjusted possible confounding factors. These results proved that the baseline level of TyG was associated with the risk of NAFLD, the higher of TyG, the higher incidence of NAFLD.

Table 2 relationship between TyG index and the risk of NAFLD

	n	TyG index		
		unadjusted	Model 1	Model 2
As continuous	50037	1.697(1.619,1.779)	1.577(1.504,1.653)	1.265(1.200,1.334)
Quartile 1	12556	Reference	Reference	Reference
Quartile 2	12458	1.056(0.971,1.149)	1.035 (0.951,1.126)	0.980(0.895,1.073)
Quartile 3	12522	1.300(1.200,1.408)	1.259(1.162,1.364)	1.090(0.999,1.190)
Quartile 4	12501	1.972(1.832,2.123)	1.783(1.655,1.920)	1.314(1.234,1.457)
<i>P</i> for trend		<0.001	<0.001	<0.001

Model 1: adjusted age and sex;

Model 2: model 1 plus living alone, current smoking, exercise, waist-to-height ratio, systolic blood pressure, diastolic blood pressure, alanine aminotransferase, aspartate aminotransferase, total bilirubin, total cholesterol and diabetes.

2.3 The ability of TyG to predict NAFLD

The receiver operating characteristic curves (ROC) were used to evaluate the ability of baseline level of TyG to predict the development of NAFLD. The best cutoff value for TyG index to diagnosis NAFLD was 8.63 (sensitivity: 0.48, specificity: 0.67), and its corresponding area under the receiver operating characteristic curves (AUCs) was 0.60 (95%CI:0.58,0.61) , showed in **Figure 2**.

Figure 2 ROC curve of TyG on NAFLD

Receiver operating characteristics (ROC) curves for baseline TyG to predict NAFLD among 60 years old or more. The ROC area was 0.594(0.590 - 0.599). TyG, triglyceride glucose; NAFLD, nonalcoholic fatty liver diseases.

2.4 Restricted cubic spline analysis to evaluate the relationship between TyG and NAFLD

In order to further explore the relationship between TyG and the risk of NAFLD, restricted cubic spline graph was used to analyze the dose-response relationship between TyG and the incidence of NAFLD. As showed in **Figure 3**, there was a nonlinear relationship between level of TyG index and the risk of NAFLD based on the adjusted Cox regression model. TyG index significantly increased the risk of NAFLD

when it was 8.63 and above. This result indicated that higher level of TyG was associated with higher incidence of NAFLD.

Figure 3 Restricted cubic spline graph of risk of TyG index and the development of NAFLD.

Multivariate adjusted hazard ratios of NAFLD increasing during follow-up when the baseline level of TyG index 8.63 and above. Adjusted variables including age, sex, living alone, current smoking, exercise, waist-to-height ratio, systolic blood pressure, diastolic blood pressure, alanine aminotransferase, aspartate aminotransferase, total bilirubin, total cholesterol. TyG, triglyceride glucose; NAFLD, nonalcoholic fatty liver diseases; CI, confidence interval.

2.5 Mediation effects

In previous analysis we found that WHtR was associated with the incidence of NAFLD as well as the relationship between WHtR and TyG index ($P < 0.05$, and the data wasn't showed). Based on WHtR would lead to IR, and TyG index was a reliable and cheap surrogate indicate for IR, so there might be a mediate effect of TyG index between WHtR and NAFLD. Then mediation analysis was used to certificated whether there was a mediating effect and how TyG index affect the relationship between WHtR and NAFLD. Results (showed in **Table 3 and Figure 4**) of mediation analysis showed that the total effect of WHtR on NAFLD was 1.476 (1.437,1.517), and the direct effect was 1.463(1.842,1.950), TyG index play a partial role and the indirect effect was 1.019 (1.006,1.011).This result may indicate that abdominal obesity may lead to disorders of glycolipid dyslipidemia, and then lead to an increase of the TyG index.

Table 3 Mediation analysis of the relationship between TyG index and NAFLD by WHtR

Effect	HR (95%CI)
Total effect	1.476 (1.437,1.517)
Direct effect	1.463 (1.842,1.950)
Indirect effect	1.009(1.006,1.011)

Figure 4 The mediate effect of TyG index on WHtR and NAFLD.

The effect of WHtR on NAFLD was mediated by baseline level TyG index by adjusted potential confounders age, sex, living alone, current smoking, exercise, systolic blood pressure, diastolic

1
2
3
4 blood pressure, alanine aminotransferase, aspartate aminotransferase, total bilirubin, total
5
6 cholesterol.
7
8

9 10 **3. Discussion**

11 With the acceleration of the aging process, the health in the elderly has gradually
12 become an important issue in society. NAFLD, a common liver disease in China, also
13 has become one of the main health problems of the elderly. Although there were some
14 researches about TyG index and NAFLD, research about TyG index and the incidence
15 of NAFLD in the older has not been reported.
16
17

18 In this retrospective cohort study, we found the incidence of NAFLD was 3.80/100
19 pearson-years among the elderly over 60, which was lower than a cohort study of Korea
20 (the incidence of NAFLD was 4.84/100 pearson-years)[25]. This might be due to the
21 age of the subjects in Korean cohort study(mean age are 36.1) was younger than ours,
22 and age could affect the prevalent and severity of NAFLD[26]. What's more, the
23 incidence of NAFLD decreased with the age increased in this study, and the P_{value} for
24 trend <0.001 (the data did not show in this research) A retrospective cohort study on TyG
25 index and NAFLD in Japan also found that higher TyG was associated with higher risk
26 of NAFLD, which was consistent with our results[13]. While, as far as we know, this
27 research is the first study to focus on the effect of TyG index on the incidence of
28 NAFLD in the elderly. Our study also indicated relationship between TyG index was
29 nonlinear, the incidence of NAFLD would increase significantly when TyG is above
30 8.63. What's more, the results of the mediation effect suggested that TyG index was
31 not an independent factor for the development of NAFLD, but a partial mediator
32 between WHtR and NAFLD.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 The results of ROC suggested that 8.63 was the best cutoff value of TyG index for
51 predicting the prevalent of NAFLD, which was close to the research of L. Fedchuk et
52 al[9]. TyG index as an inexpensive and reliable surrogate index for IR, and IR plays an
53 important role in the development and progression of NAFLD, even in the absence of
54 diabetes, IR can lead to changes from normal liver to NAFL to NASH[10]. Large
55
56
57
58
59
60

1
2
3
4 numbers of studies have confirmed that IR is closely related to the occurrence and
5 development of NAFLD[27-30].
6

7 The mechanism of IR on NAFLD could be explained by the following reasons. On one
8 hand, IR has a direct effect on metabolism of glucose, IR participates in the occurrence
9 and development of NAFLD by disturbing the glucose and lipid metabolism disorder
10 of the liver[27]. Insulin resistance reduces glucose uptake in adipose tissue and muscle
11 and hydrolysis of triglycerides in adipose tissue as well as increases the conversion of
12 glucose to fatty acids in the liver. Furthermore, IR could also increase de novo
13 lipogenesis by activating sterol regulatory element binding protein (SREBP1), high
14 insulin levels can increase the uptake of free fatty acids in the liver and the synthesis of
15 TG, causing excessive accumulation of fat in the liver, which could be a start of
16 steatosis and then lead to the occurrence of NAFLD[7, 31, 32]. On the other hand, IR
17 is always linked to chronic mild inflammation, by releasing inflammatory factors such
18 as TNF α , IL-6, IL-1 and monocyte chemoattractant protein-1, immune cells or
19 adipocytes can in turn promote IR and participate the developing and progressing of
20 NAFLD[33, 34].
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 Obesity is a key factor in development and progress of NAFLD. Studies also have found
36 the subjects with NAFLD have the higher level of BMI, and higher BMI was associated
37 with the risk of NAFLD[35, 36]. Overweight/obesity participates in the development of
38 NAFLD through insulin resistance. While growing evidence suggested that the
39 determinant of insulin resistance is not the degree of obesity, but the distribution of fat,
40 abdominal fat accumulation is related to insulin resistance[37, 38]. Studies also shown
41 that 2-h glucose and insulin resistance are significantly increased with higher visceral
42 fat than those with lower abdominal fat in obese adolescents [39, 40]. Central obesity
43 can lead to inflammatory, oxidative stress and metabolic disorders, which are related to
44 the development of insulin resistance[41, 42]. In this study, WHtR, as an indicator of
45 central obesity, was associated with NAFLD, and the effect was mediated by TyG index
46 in this study. Which could be explained by the central obesity leads to the TyG index
47 increasing, and thus leads to the incidence of NAFLD.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 The major strength of this study was a large sample size retrospective cohort study
5 which included 50037 aged more than 60 years old, and cohort study could better reflect
6 the real relationship between TyG index and NAFLD. Moreover, nonlinear relationship
7 between TyG index and NAFLD was found by cubic spline graph and the mediation
8 effect of TyG index between WHtR and NAFLD in this study. However, there were
9 several limitations in this study. First, the diagnosis of NAFLD was based on the results
10 of abdominal ultrasound instead of liver biopsy and only provide information on
11 whether there was the presence of NAFLD. However, it is difficult to find mild steatosis
12 by ultrasonography, the incidence of NAFLD could be underestimated[31, 43]. Then
13 the subjects could not respond their history of lipid-lowering therapy or antidiabetic
14 drugs as they were elder; So information about therapy was missing in the data.
15 Additionally, we could not evaluate the relationship between TyG index and different
16 NAFLD severity. In addition, we lack other more accurately index which can reflect
17 the abdominal obesity status, even though we used WHtR to indicate the abdominal
18 obesity we were unable to assess the more accurately visceral fat index and the
19 prevalent of NAFLD.

20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35 In conclusion, high baseline level of TyG index is significantly associated with the
36 higher risk of NAFLD. In addition, TyG index play a partial mediating role in the
37 relationship between WHtR and NAFLD, our results also indicated that TyG index may
38 be a potential marker for NAFLD. So measured the TyG index to assess the risk of
39 NAFLD routinely in clinical practice is useful.

40 41 42 43 44 45 **Acknowledgements:**

46
47 This research was funded by the National Natural Science Foundation of China (Grant
48 No. 81673165), the National Key Research and Development Programme of China
49 (Grant Nos 2017YFC1307705 and 2016YFC0106907). In addition, the authors are
50 grateful to Junxing Fan for helping with the quality control of the data. The funders had
51 no role in the study design, data collection and analysis, decision to publish, or
52 preparation of the manuscript.

53 54 55 56 57 58 59 **Author Contributions:**

1
2
3
4 H.C. and Q.L. designed the study. H.C., S.L., X.C., Z.S., G.W and J.H. participated in
5 the data collection and analysis. H.C. and A.A. drafted this manuscript, H.C. S.L., and
6 S.S. interpreted the data. S.S and Q.L. reviewed and revised this manuscript. All authors
7
8
9
10 have approved the final manuscript.

11 **Financial support:**

12
13
14 This research was funded by the National Natural Science Foundation of China (Grant
15 No. 81673165), the National Key Research and Development Programme of China
16
17 (Grant Nos 2017YFC1307705 and 2016YFC0106907)
18
19
20
21
22

23 **Conflict of Interest:**

24 All authors have no conflicts of interest.

25
26
27 **Patient and public involvement:** Participants were not involved in the
28 recruitment and conduct of the study
29

30
31 **Patient consent for publication:** Given the retrospective nature of the research,
32 the requirement for informed consent was waived. Patients were not involved in the
33 recruitment and conduct of the study. The study protocol was approved by ethics
34 committee of Zhengzhou University in China.
35
36
37
38

39 **Ethics approval:**

40
41 The study protocol was approved by ethics committee of Zhengzhou University in
42 China (approval number: ZZURIB202004). Given the retrospective nature of the
43 research, the requirement for informed consent was waived.
44
45
46
47

48 **Provenance and peer review:** Not commissioned; externally peer reviewed
49

50
51 **Data availability statement:** The datasets generated and/or analyzed during the
52 current study are available upon request.
53
54

55
56 **Open access:** This is an open access article distributed in accordance with the
57 Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
58 permits others to distribute, remix, adapt, build upon this work non-commercially, and
59
60


license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

reference

- (1) Finck BN. Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis. *Diabetes*. 2018;67:2485-93.
- (2) Yu Y, Cai JJ, She ZG, et al. Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases. *Adv Sci*. 2019;6.
- (3) Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology*. 2019;156:1264-+.
- (4) Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. *Nat Rev Gastroenterol Hepatol*. 2013;10:330-44.
- (5) Schindhelm RK, Heine RJ, Diamant M. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. *Diabetes Care*. 2007;30:e94; author reply e5.
- (6) Goldberg D, Ditah IC, Saeian K, et al. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. *Gastroenterology*. 2017;152:1090-+.
- (7) Watt MJ, Miotto PM, De Nardo W, et al. The liver as an endocrine organ - linking NAFLD and insulin resistance. *Endocr Rev*. 2019.
- (8) Baratta F, Pastori D, Polimeni L, et al. Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance. *American Journal of Gastroenterology*. 2017;112:1832-9.
- (9) Fedchuk L, Nascimbeni F, Pais R, et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. *Alimentary Pharmacology & Therapeutics*. 2014;40:1209-22.
- (10) Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. *Nat Rev Gastro Hepat*. 2019;16:377-86.
- (11) Du T, Yuan G, Zhang M, et al. Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance. *Cardiovasc Diabetol*. 2014;13:146.
- (12) Nor NSM, Lee S, Bacha F, et al. Triglyceride glucose index as a surrogate measure of insulin sensitivity in obese adolescents with normoglycemia, prediabetes, and type 2 diabetes mellitus: comparison with the hyperinsulinemic-euglycemic clamp. *Pediatr Diabetes*. 2016;17:458-65.
- (13) Kitae A, Hashimoto Y, Hamaguchi M, et al. The Triglyceride and Glucose Index Is a Predictor of Incident Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. *Can J Gastroenterol Hepatol*. 2019;2019:5121574.
- (14) Houry M, Manlhiot C, McCrindle BW. Role of the Waist/Height Ratio in the Cardiometabolic Risk Assessment of Children Classified by Body Mass Index. *J Am Coll Cardiol*. 2013;62:742-51.
- (15) Xi B, Mi J, Zhao M, et al. Trends in abdominal obesity among U.S. children and adolescents. *Pediatrics*. 2014;134:e334-9.
- (16) Huang X, Wang QY, Liu TT, et al. Body fat indices as effective predictors of insulin resistance in


- 1
2
3 obese/non-obese polycystic ovary syndrome women in the Southwest of China. *Endocrine*. 2019;65:81-5.
- 4 (17) Motamed N, Rabiee B, Hemasi GR, et al. Body Roundness Index and Waist-to-Height Ratio are
5 Strongly Associated With Non-Alcoholic Fatty Liver Disease: A Population-Based Study. *Hepat Mon*.
6 2016;16:e39575.
- 7
8 (18) Zheng RD, Chen ZR, Chen JN, et al. Role of Body Mass Index, Waist-to-Height and Waist-to-Hip
9 Ratio in Prediction of Nonalcoholic Fatty Liver Disease. *Gastroenterol Res Pract*. 2012;2012:362147.
- 10 (19) Zhang X, Wan Y, Zhang S, et al. Nonalcoholic fatty liver disease prevalence in urban school-aged
11 children and adolescents from the Yangtze River delta region: a cross-sectional study. *Asia Pac J Clin*
12 *Nutr*. 2015;24:281-8.
- 13 (20) Ramirez-Velez R, Izquierdo M, Correa-Bautista JE, et al. Grip Strength Moderates the Association
14 between Anthropometric and Body Composition Indicators and Liver Fat in Youth with an Excess of
15 Adiposity. *J Clin Med*. 2018;7.
- 16 (21) Lin MS, Lin TH, Guo SE, et al. Waist-to-height ratio is a useful index for nonalcoholic fatty liver
17 disease in children and adolescents: a secondary data analysis. *Bmc Public Health*. 2017;17.
- 18 (22) Procino F, Misciagna G, Veronese N, et al. Reducing NAFLD-screening time: A comparative study
19 of eight diagnostic methods offering an alternative to ultrasound scans. *Liver Int*. 2019;39:187-96.
- 20 (23) Kojima S, Watanabe N, Numata M, et al. Increase in the prevalence of fatty liver in Japan over the
21 past 12 years: analysis of clinical background. *J Gastroenterol*. 2003;38:954-61.
- 22 (24) Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in public
23 health research. *Stat Med*. 2010;29:1037-57.
- 24 (25) Jang EH, Chang Y, Ryu S, et al. Cardiovascular Health Metrics in the Development and Regression
25 of Nonalcoholic Fatty Liver Disease: A Cohort Study. *J Clin Med*. 2019;8.
- 26 (26) Petta S, Eslam M, Valenti L, et al. Metabolic syndrome and severity of fibrosis in nonalcoholic fatty
27 liver disease: An age-dependent risk profiling study. *Liver Int*. 2017;37:1389-96.
- 28 (27) Khan RS, Bril F, Cusi K, et al. Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease.
29 *Hepatology (Baltimore, Md)*. 2018.
- 30 (28) Sung KC, Lee MY, Lee JY, et al. Natural course of fatty liver in 36,195 South Korean adults.
31 *Scientific reports*. 2019;9:9062.
- 32 (29) Ballestri S, Nascimbeni F, Romagnoli D, et al. Type 2 Diabetes in Non-Alcoholic Fatty Liver
33 Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight. *Int J Mol Sci*.
34 2016;17:355.
- 35 (30) Sookoian S, Pirola CJ. Systematic review with meta-analysis: risk factors for non-alcoholic fatty
36 liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese
37 patients. *Aliment Pharmacol Ther*. 2017;46:85-95.
- 38 (31) Wong VWS, Chan WK, Chitturi S, et al. Asia-Pacific Working Party on Non-alcoholic Fatty Liver
39 Disease guidelines 2017Part 1: Definition, risk factors and assessment. *J Gastroen Hepatol*. 2018;33:70-
40 85.
- 41 (32) Gastaldelli A. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?
42 *Clin Sci*. 2017;131:2701-4.
- 43 (33) Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. *Cell*
44 *Metab*. 2012;15:635-45.
- 45 (34) Baeck C, Wehr A, Karlmark KR, et al. Pharmacological inhibition of the chemokine CCL2 (MCP-
46 1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. *Gut*.
47 2012;61:416-26.
- 48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 (35) Tang ZL, Pham M, Hao YM, et al. Sex, Age, and BMI Modulate the Association of Physical
4 Examinations and Blood Biochemistry Parameters and NAFLD: A Retrospective Study on 1994 Cases
5 Observed at Shuguang Hospital, China. *BioMed research international*. 2019.
6
7 (36) Liu M, Wang J, Zeng J, et al. Association of NAFLD With Diabetes and the Impact of BMI Changes:
8 A 5-Year Cohort Study Based on 18,507 Elderly. *J Clin Endocrinol Metab*. 2017;102:1309-16.
9
10 (37) Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. *N Engl J*
11 *Med*. 2014;371:1131-41.
12
13 (38) Caprio S, Perry R, Kursawe R. Adolescent Obesity and Insulin Resistance: Roles of Ectopic Fat
14 Accumulation and Adipose Inflammation. *Gastroenterology*. 2017;152:1638-46.
15
16 (39) Taksali SE, Caprio S, Dziura J, et al. High visceral and low abdominal subcutaneous fat stores in
17 the obese adolescent: a determinant of an adverse metabolic phenotype. *Diabetes*. 2008;57:367-71.
18
19 (40) D'Adamo E, Cali AM, Weiss R, et al. Central role of fatty liver in the pathogenesis of insulin
20 resistance in obese adolescents. *Diabetes Care*. 2010;33:1817-22.
21
22 (41) Kursawe R, Dixit VD, Scherer PE, et al. A Role of the Inflammasome in the Low Storage Capacity
23 of the Abdominal Subcutaneous Adipose Tissue in Obese Adolescents. *Diabetes*. 2016;65:610-8.
24
25 (42) Stienstra R, van Diepen JA, Tack CJ, et al. Inflammasome is a central player in the induction of
26 obesity and insulin resistance. *P Natl Acad Sci USA*. 2011;108:15324-9.
27
28 (43) Wong VW, Adams LA, de Ledinghen V, et al. Noninvasive biomarkers in NAFLD and NASH -
29 current progress and future promise. *Nat Rev Gastroenterol Hepatol*. 2018;15:461-78.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




160x90mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Receiver operating characteristics (ROC) curves for baseline TyG to predict NAFLD among 60 years old or more. The ROC area was 0.594(0.590 - 0.599). TyG, triglyceride glucose; NAFLD, nonalcoholic fatty liver diseases.

119x90mm (300 x 300 DPI)



Multivariate adjusted hazard ratios of NAFLD increasing during follow-up when the baseline level of TyG index 8.63 and above. Adjusted variables including age, sex, living alone, current smoking, exercise, waist-to-height ratio, systolic blood pressure, diastolic blood pressure, alanine aminotransferase, aspartate aminotransferase, total bilirubin, total cholesterol. TyG, triglyceride glucose; NAFLD, nonalcoholic fatty liver diseases; CI, confidence interval.

123x90mm (300 x 300 DPI)



The effect of WHtR on NAFLD was mediated by baseline level TyG index by adjusted potential confounders age, sex, living alone, current smoking, exercise, systolic blood pressure, diastolic blood pressure, alanine aminotransferase, aspartate aminotransferase, total bilirubin, total cholesterol.

160x90mm (300 x 300 DPI)

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	1,2 2,3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3,4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4,5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	4,5 N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4,5
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4,5
Bias	9	Describe any efforts to address potential sources of bias	N/A
Study size	10	Explain how the study size was arrived at	4
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5,6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	5,6 N/A N/A N/A N/A
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	6,7 N/A 4
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	6,7 N/A 6
Outcome data	15*	Report numbers of outcome events or summary measures over time	6,7

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7,8
2			(b) Report category boundaries when continuous variables were categorized	7,8
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
4				
5	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
6				
7				
8				
9				
10				
11	Discussion			
12	Key results	18	Summarise key results with reference to study objectives	10
13	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12
14				
15	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10,11,12
16				
17	Generalisability	21	Discuss the generalisability (external validity) of the study results	12
18				
19				
20				
21	Other information			
22	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13
23				
24				
25				

26 *Give information separately for exposed and unexposed groups.

27
28 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and
29 published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely
30 available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at
31 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is
32 available at <http://www.strobe-statement.org>.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Relationship between triglyceride glucose index and the incidence of nonalcoholic fatty liver disease in the elderly: a retrospective cohort study in China

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-039804.R1
Article Type:	Original research
Date Submitted by the Author:	23-Jul-2020
Complete List of Authors:	Chen, Huanan; Zhengzhou University, Department of Nutrition and Food Hygiene, College of Public Health Li, Sangsang; Xinyang Central Hospital, Medical record room Amoah, Adwoa Nyantakyiwaa ; Zhengzhou University, Department of Nutrition and Food Hygiene, College of Public Health Bo, Yacong; The Chinese University of Hong Kong, Jockey Club School of Public Health and Primary Care Chen, Xuejiao; Zhengzhou University, Department of Social Medicine, College of Public Health Shi, Zhan; Henan University of Traditional Chinese Medicine, Department of Pharmacy, Zhengzhou People's Hospital Wan, Guodong; Henan Province Health and Family Planning Commission, Health Commission of Xinzheng Huang, Jian; Henan Province Center for Disease Control and Prevention, Henan Province Center for Disease Control and Prevention shi, songhe; Zhengzhou University, Department of Epidemiology and Biostatistics Lyu, Quanjun ; Zhengzhou University, Department of Nutrition and Food Hygiene, College of Public Health; Zhengzhou University, Department of Nutrition, The First Affiliated Hospital of Zhengzhou University
Primary Subject Heading:	Gastroenterology and hepatology
Secondary Subject Heading:	Gastroenterology and hepatology
Keywords:	Hepatobiliary disease < GASTROENTEROLOGY, Lipid disorders < DIABETES & ENDOCRINOLOGY, PUBLIC HEALTH

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Relationship between triglyceride glucose index and the incidence of nonalcoholic fatty liver disease in the elderly: a retrospective cohort study in China

Chen Huanan¹, Li Sangsang², Amoah, Adwoa Nyantakyiwaa¹, Bo Yacong³ Chen Xuejiao⁴, Shi Zhan⁵, Wan Guodong⁶, Huang Jian⁷, Shi Songhe⁸, Lyu Qianjun^{1,9}.

1. Department of Nutrition and Food Hygiene, College of Public Health, Zhengzhou University, Zhengzhou, Henan, P.R. China.
2. Medical record room, Xinyang Central Hospital, Xinyang, Henan, P.R. China.
3. Jockey Club School of Public Health and Primary Care, the Chinese University of Hong Kong
4. Department of Social Medicine, College of Public Health, Zhengzhou University, Zhengzhou, Henan, P.R. China.
5. Department of Pharmacy, Zhengzhou People's Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, P.R. China.
6. Health Commission of Xinzheng, Henan Province Health and Family Planning Commission, Henan, P.R. China.
7. Central for Disease Control of Xinzheng, Henan Province Center for Disease Control and Prevention, Henan, P.R. China.
8. Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, P.R. China.
9. Department of Nutrition, The First Affiliated Hospital of Zhengzhou University, Henan, P.R. China

Corresponding Authors:

Qianjun Lyu, PhD, Department of Nutrition and Food Hygiene, College of Public Health, Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, 100 Science Road, Zhengzhou, China. Phone: (0371) 67781923, email: lqjnutr@zzu.edu.cn.

Songhe Shi, PhD, Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, 100 Science Road, Zhengzhou, China. Phone:(0371)

67781254, email: zzussh@126.com.

Abstracts

Objective: Nonalcoholic fatty liver disease (NAFLD) is one of the major causes of liver-related diseases but relationship between triglyceride glucose (TyG) and NAFLD in the elderly is not reported yet. In this study, we investigated the role of TyG index for predicting the incidence of NAFLD in the elderly.

Design and setting : This is a prospective cohort study in Henan, China, from 2011-2018.

Participants and Methods : In total, 46,693 elderly who participated in a routine physical examination programme from 2011 to 2018 were included in this study. TyG index was calculated as \ln [fasting triglyceride (mg/dl) \times fasting plasma glucose (mg/dl)/2], while NAFLD was defined as hepatic steatosis after excluding other causes based on the results of abdominal ultrasonography; Cox regression model was performed to explore the relationship between TyG index and NAFLD. Also, mediation effect was used to analyze the role of the TyG index in WHtR and NAFLD.

Results: During the 149041.50 person-years follow-up, a total of 5660 NAFLD events occurred (3.80/100 person-years). After adjusting for potential confounding factors, quartiles 4 of TyG index significantly increased the incidence of NAFLD compared with quartile 1, the hazard ratios (HRs) and 95% confidence intervals (CI) were 1.314(1.234,1.457). In addition, TyG index played a partial mediating role in the relationship between WHtR and NAFLD and indirect effect was 1.009(1.006,1.011).

Conclusion: Higher TyG index was associated with higher risk of NAFLD in the aged and therefore, TyG index may be a novel predictor for incidence of NAFLD. Further, regular examination and evaluation of the TyG index might be useful for controlling the occurrence of NAFLD.

Key words: Nonalcoholic fatty liver disease; Triglyceride glucose index; Waist-to-height ratio; Mediation effect.

Strengths and limitations of this study :

1
2
3
4 Data for this cohort study were retrieved from a large regular physical examination in
5 Henan, China.

6
7 Restricted cubic spline analysis and mediation effect were used in this study, which can
8 reflect the relationship between TyG index and NAFLD more realistically.

9
10 The sample size and statistical power were sufficient in this study.

11
12 The severity of disease in this cohort study was not available when data were retrieved.
13 Some participants were excluded in this study because they did not have abdominal
14 ultrasound testing.

15 16 17 18 19 **Introduction**

20
21 Nonalcoholic fatty liver disease(NAFLD) encompasses a series of spectrum of liver
22 diseases, ranging from simple steatosis, nonalcoholic steatohepatitis, cirrhosis to
23 hepatocellular carcinoma[1]. With the change of lifestyle and increase of obesity,
24 NAFLD currently exceeds viral hepatitis and is becoming the most common chronic
25 liver disease, affecting about a quarter of the common population in the world[2, 3].
26 NAFLD is one of the major causes of liver-related disease such as cirrhosis,
27 hepatocellular carcinoma and liver transplantation. Moreover, NAFLD is also
28 associated with higher prevalence and incidence of cardiovascular disease such as
29 coronary, cerebrovascular and peripheral vascular disease [4, 5]. In the next decade,
30 NAFLD is expected to become the leading cause for liver transplantation in the United
31 States instead of hepatitis C[6].

32
33 The development of NAFLD is a complex process involving genetic and environmental
34 factors. As an organ of metabolism, the disorder of glucose and lipid metabolism plays
35 an important role in the progress of NAFLD[7]. Several studies found that IR could
36 increase the risk of NAFLD even without the existence of T2DM and IR may be the
37 genesis of steatosis[7-10].Furthermore, as an early marker of IR, TyG has been
38 proposed to be an inexpensive and reliable surrogate to IR[11, 12] Yet researches about
39 the relationship between TyG index and the risk of NAFLD are limited [9, 13].
40 Additionally, as far as we know, the association between TyG index and the incidence
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

of NAFLD in the older has not been reported.

WHtR is a maker of abdominal obesity and studies have also reported that WHtR is related to IR[14, 15] and also the higher risk of NAFLD [16-22]. Whether there is an existing effect of TyG index on the relationship between WHtR and NAFLD and how it affects NAFLD is still unclear. This retrospective cohort study therefore sought to explore the relationship between baseline level of TyG index and the incidence of NAFLD.

1.Participants and methods

1.1 Subjects:

We retrospectively analyzed the 99,997 subjects who had the data of liver ultrasonography, fasting triglyceride as well as fasting plasma glucose in physical examination programme in Xinzheng, Henan Province, in Central China City from January 2011 to December 2018. This physical examination programme was for the local residents over 60 years old and was supported by the government of Xinzheng, Henan Province in China. Individuals with any of the following criteria were excluded:1) missing follow-up; 2) subjects with NAFLD at baseline;3) subjects with hepatitis B or C virus or had the history of excess alcohol intake (the threshold for women <20 g/d and <30 g/d for men). A total of 46,693 eligible participants were included in this cohort study (**Figure 1**). The datasets generated and/or analyzed during the current study are available upon request. Given the retrospective nature of the research, the requirement for informed consent was waived. Patients were not involved in the recruitment and conduct of the study. The study protocol was approved by ethics committee of Zhengzhou University in China (Approve number: ZZURIB202004).

Figure 1 Flow chart for participants exclusions performed

1.2 Data collection

Demographic data and clinical information of the subjects were collected when they underwent health check-up. Demographic data included age, sex, excess alcohol intake

(yes/no), current smoking status (yes/no), lives alone(yes/no) and exercises regularly(yes/no). The definition of current smoking was that subjects used to smoke 100 cigarettes or above in their lifetime, and now is still smoking regularly. Excessive drinking was defined as drinking more than 30g /d for men and 20g/d for women. Exercising regularly was defined as more than 3 times a week, and 30 minutes moderate intensity exercise each time. The clinic records included anthropometric measurements (such as height, weight, blood pressure, waist circumference) and laboratory data. Height measurement required the subjects without shoes, stand straight on the ground, and their hips and heels against the wall, to measure the weight, the participants were without shoes and wore light clothing. Blood pressure of the subjects in a sitting position after 5 minutes of rest was measured twice by an electronic sphygmomanometer (Omron HEM-7125, Kyoto, Japan), and the mean value of the two measurements was recorded. Waist circumference was measured at the midpoint of the distance between the lowest costal ridge and the upper border of the iliac crest. After fasting for 8 hours, the blood samples of subjects were collected to determine the level of fasting plasma glucose (FPG), total cholesterol (TC) and triglyceride (TG) using a biochemical detector (DIRUI CS380, Changchun, China). Alanine aminotransferase (ALT), aspartate transaminase (AST) and total bilirubin (TB) was detected by (DIRUI CS380, Changchun, China). The TyG index were calculated as the \ln [fasting TG (mg/dl) \times FPG (mg/dl)/2]. WHtR was defined as waist circumference(cm)/height(cm).

1.3 NAFLD definition

All participants of this study underwent liver ultrasonography (SIUI CZXL-38G, Shantou, China). The results of ultrasound prompted the existence of steatohepatitis: enhanced liver echogenicity, echogenicity greater in liver than kidneys, deep attenuation and vascular blurring[23] and after excluding the steatohepatitis caused by alcohol, viruses and drugs was defined as NAFLD. All ultrasound examinations were performed by an experienced professional radiologist.

1.4 Statistics

Categorical variables were showed as proportions while continuous variables were

presented as means \pm standard deviation (SD) or median (interquartile range) (IQR). ANOVA/two - paired sample t tests (continuous variables, normal distribution) and chi-square tests (categorical variables) were used to compare the difference in different groups. Logistic regression for categorical variables and linear regression for continuous variables were used to obtain the *P* value for trend.

Cox regression models were used to explore the relationship between TyG index and the incidence of NAFLD, the lowest quartiles of TyG index was defined as the reference. Hazards ratio (*HR*) and confidence interval (*CI*) of NAFLD in quartiles and continuous were expressed in separate models. To assess the relationship across increasing quartiles, *P* value for trend tests were used by entering median value in each quartile in Cox regression models.

AUCs were used to evaluate the ability of the baseline TyG index to predict the risk of NAFLD. Restricted cubic spline models were used to explore whether there was a nonlinear relationship between continuous and occurrence of NAFLD [24]. Mediation analysis used a Cox regression to study the mediate effect of TyG index between WHtR and NAFLD.

Mediation analysis was conducted using R version 3.5.0 (R Foundation for Statistical Computing, Vienna, Austria), and Restricted cubic spline were performed in Stata v 12.0 (Stata Corp, College Station, TX, USA). The other analyses were performed by SPSS software, version 21.0 (SPSS Inc, Chicago). Probability values for statistical tests, where two-tailed *P*-values<0.05 were regarded as significant.

2. Result

2.1 Baseline Characteristics of included subjects

A total of 46,693 subjects were included in this study. The baseline characteristics of included participants based on follow-up were presented in **Table 1**. The mean age of subjects was 68.91 (7.17) and 48.89% were men. The average follow-up was 3.19(1.52) years, during the 149041 person-years follow-up, 5660 subjects occurred NAFLD (3.80/100 person-years). Subjects with NAFLD with higher BMI, WHtR, TC, FBG, DBP, SBP, ALT, and TB and the incidence of NAFLD was higher in younger, current

smoking, regular exercise, with diabetes and hypertension but the baseline level of AST had no association with the incidence of NAFLD.

Table 1 baseline characteristics of included subjects according to the follow-up outcome

variables	No NAFLD (n=41033)	NAFLD (n=5660)	P value
Men, n (%) †	20799(50.69)	2033(35.92)	<0.001
Age (years) ‡	69.18±7.27	66.93±6.00	<0.001
Current smoking, n (%) †	6846 (16.70)	594(10.51)	<0.001
Exercise, n (%) †	7865(19.22)	1131(20.02)	<0.001
Live alone, n (%) †	8772(21.38)	1015(17.93)	<0.001
Diabetes, n (%) †	5554(13.54)	1344(23.75)	<0.001
Hypertension, n (%) †	15945 (38.86)	2952(52.16)	<0.001
WHtR‡	0.51±0.06	0.54±0.07	<0.001
BMI‡	23.62±2.85	26.02±3.10	<0.001
SBP (mmHg) ‡	132.62±19.38	135.32±19.76	<0.001
DBP (mmHg) ‡	78.92±10.34	80.91±10.33	<0.001
FPG (mmol/L) §	5.20(4.70-5.70)	5.30(4.80-5.93)	<0.001
TC (mmol/L) §	4.59(4.01-5.21)	4.69(4.09-5.38)	<0.001
TG (mmol/L) §	1.10(0.81-1.47)	1.28(0.90-1.77)	<0.001
TB (µmol/L) §	11.51(8.60-14.10)	11.30(8.30-13.80)	<0.001
ALT(U/L) §	18.00(13.00-24.50)	18.60(14.00-25.00)	<0.001
AST(U/L) §	21.80(16.89-26.90)	21.90(16.89-27.00)	0.892
TyG‡	8.43±0.54	8.61±0.59	<0.001

†: n (%); ‡: mean (SD); §: median (IQR)

Abbreviations: BMI, body mass index; WHtR, waist-to-height ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; TC, triglycerides; TG, triglyceride; TB, total bilirubin; ALT, alanine aminotransferase, AST, aspartate aminotransferase; TyG, triglyceride glucose.

2.2 Association between TyG index and NAFLD

The relationship between TyG index and the incidence of NAFLD were showed in **Table 2**. Compared with quartile 1 of TyG index, the hazard ratio (HR) and its corresponding 95% confidence interval (CI) for quartile2, quartile3, and quartile 4 were 1.056(0.971,1.149), 1.300(1.200,1.408) and 1.972(1.832,2.123), respectively. Risk for NAFLD was significantly higher with increasing quartiles of TyG for the *P* value of trend of linearity <0.001. In addition, even after adjusted possible confounding factors, the risk of quartile 3 of TyG index (1.314(1.234,1.457)) on the incidence of NAFLD still existed. In order to further verify the relationship between the TyG index and the

incidence of NAFLD, TyG index was used as continuous variables for the above analysis and the results also proved that higher level of TyG increased the risk of NAFLD (1.265(1.200,1.334)), even after adjusted possible confounding factors. These results proved that the baseline level of TyG was associated with the risk of NAFLD, thus the higher the TyG level, the higher incidence of NAFLD.

Table 2 relationship between TyG index and the risk of NAFLD

	N	TyG index		
		unadjusted	Model 1	Model 2
As continuous	50037	1.697(1.619,1.779)	1.577(1.504,1.653)	1.265(1.200,1.334)
Quartile 1	12556	Reference	Reference	Reference
Quartile 2	12458	1.056(0.971,1.149)	1.035 (0.951,1.126)	0.980(0.895,1.073)
Quartile 3	12522	1.300(1.200,1.408)	1.259(1.162,1.364)	1.090(0.999,1.190)
Quartile 4	12501	1.972(1.832,2.123)	1.783(1.655,1.920)	1.314(1.234,1.457)
<i>P</i> for trend		<0.001	<0.001	<0.001

Model 1: adjusted age and sex;

Model 2: model 1 plus living alone, current smoking, exercise, waist-to-height ratio, systolic blood pressure, diastolic blood pressure, alanine aminotransferase, aspartate aminotransferase, total bilirubin, total cholesterol and diabetes.

2.3 The ability of TyG to predict NAFLD

The receiver operating characteristic curves (ROC) were used to evaluate the ability of baseline level of TyG to predict the development of NAFLD. The best cutoff value for TyG index to diagnosis NAFLD was 8.63, and its corresponding area under the receiver operating characteristic curves (AUCs) was 0.60 (95%CI:0.58,0.61), showed in **Figure 2**.

Figure 2 ROC curve of TyG on NAFLD

Receiver operating characteristics (ROC) curves for baseline TyG to predict NAFLD among 60 years old or more. The ROC area was 0.594(0.590 - 0.599). TyG, triglyceride glucose; NAFLD, nonalcoholic fatty liver diseases.

2.4 Restricted cubic spline analysis to evaluate the relationship between TyG and NAFLD

In order to further explore the relationship between TyG and the risk of NAFLD, restricted cubic spline graph was used to analyze the dose-response relationship between TyG and the incidence of NAFLD. As shown in **Figure 3**, there was a nonlinear relationship between level of TyG index and the risk of NAFLD based on the

adjusted Cox regression model. TyG index significantly increased the risk of NAFLD when it was 8.63 and above. This result indicated that higher level of TyG was associated with higher incidence of NAFLD.

Figure 3 Restricted cubic spline graph of risk of TyG index and the development of NAFLD.

Multivariate adjusted hazard ratios of NAFLD increased during follow-up when the baseline level of TyG index was 8.63 and above. Adjusted variables including age, sex, living alone, current smoking, exercise, waist-to-height ratio, systolic blood pressure, diastolic blood pressure, alanine aminotransferase, aspartate aminotransferase, total bilirubin, total cholesterol. TyG, triglyceride glucose; NAFLD, nonalcoholic fatty liver diseases; CI, confidence interval.

2.5 Mediation effects

In previous analysis we found that WHtR was associated with the incidence of NAFLD, what's more, WHtR was also associated with TyG index ($P < 0.05$, and the data wasn't shown). If WHtR would lead to IR and TyG index was a reliable and cheap surrogate indicate for IR, then there might be a mediating effect of TyG index between WHtR and NAFLD. Therefore, mediation analysis was used to confirm whether there was a mediating effect and to what extent TyG index affect the relationship between WHtR and NAFLD. Results (presented in **Table 3 and Figure 4**) of mediation analysis revealed that the total effect of WHtR on NAFLD was 1.476 (1.437,1.517) and the direct effect was 1.463(1.842,1.950). Therefore, TyG index played a partial role and the indirect effect was 1.019 (1.006,1.011). This result may indicate that abdominal obesity may lead to disorders of glycolipid dyslipidemia which can lead to an increase of the TyG index.

Table 3 Mediation analysis of the relationship between TyG index and NAFLD by WHtR

Effect	HR (95%CI)
Total effect	1.476 (1.437,1.517)
Direct effect	1.463 (1.842,1.950)
Indirect effect	1.009(1.006,1.011)

Figure 4 The mediate effect of TyG index on WHtR and NAFLD.

1
2
3
4 The effect of WHtR on NAFLD was mediated by baseline level TyG index by adjusted potential
5 confounders namely age, sex, living alone, current smoking, exercise, systolic blood pressure,
6 diastolic blood pressure, alanine aminotransferase, aspartate aminotransferase, total bilirubin, total
7 cholesterol.
8
9
10

11 12 13 **3. Discussion** 14

15 With the acceleration of the aging process, the health in the elderly has gradually
16 become an important issue in the society. NAFLD, a common liver disease in China,
17 also has become one of the main health problems of the elderly. Although there were
18 some studies about TyG index and NAFLD, research about TyG index and the
19 incidence of NAFLD in the older adults has not been reported.
20
21
22

23 In this retrospective cohort study, we found the incidence of NAFLD was 3.80/100
24 person-years among the elderly over 60, which was lower than a cohort study of Korea
25 (the incidence of NAFLD was 4.84/100 person-years)[25]. Probably, the age of the
26 subjects in the Korean cohort study(mean age was 36.1) was younger than ours and age
27 could affect the prevalence and severity of NAFLD[26]. Additionally, the incidence of
28 NAFLD decreased as the age increased in this study and the $P_{\text{value for trend}} < 0.001$ (data
29 not presented in this research). A retrospective cohort study on TyG index and NAFLD
30 in Japan also found that higher TyG was associated with higher risk of NAFLD, which
31 was consistent with our results[13]. As far as we know, this research is the first study
32 to focus on the effect of TyG index on the incidence of NAFLD in the elderly in China.
33 Our study also reported the relationship between TyG index was nonlinear hence the
34 incidence of NAFLD would increase significantly when TyG is above 8.63.
35 Furthermore, the results of the mediation effect suggested that TyG index was not an
36 independent factor for the development of NAFLD, but a partial mediator between
37 WHtR and NAFLD.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 The results of ROC suggested that 8.63 was the best cutoff value of TyG index for
55 predicting the incidence of NAFLD, which is consistent with a study by Fedchuk et
56 al[9]. TyG index is an inexpensive and reliable surrogate index for IR and plays an
57
58
59
60

1
2
3
4 important role in the development and progression of NAFLD. Consequently, even in
5 the absence of diabetes, IR can lead to changes from normal liver to NAFL to
6 NASH[10]. Various studies have confirmed that IR is closely related to the occurrence
7 and development of NAFLD[27-30].
8
9

10
11 The mechanism of IR on NAFLD could be explained by the following reasons. On one
12 hand, IR has a direct effect on metabolism of glucose and participates in the occurrence
13 and development of NAFLD by disturbing the glucose and lipid metabolism disorder
14 of the liver[27]. Insulin resistance reduces glucose uptake in the adipose tissues and
15 muscles while the hydrolysis of triglycerides in adipose tissue as well increases the
16 conversion of glucose to fatty acids in the liver. Moreover, IR could also increase de
17 novo lipogenesis by activating sterol regulatory element binding protein (SREBP1).
18 High insulin levels can increase the uptake of free fatty acids in the liver and the
19 synthesis of TG, causing excessive accumulation of fat in the liver, which could
20 initiate steatosis and then lead to the occurrence of NAFLD[7, 31, 32]. On the other
21 hand, IR is always linked to chronic mild inflammation by releasing inflammatory
22 factors such as TNF α , IL-6, IL-1 and monocyte chemoattractant protein-1, immune
23 cells or adipocytes which can in turn promote IR and participate in the development
24 and progression of NAFLD[33, 34].
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 Obesity is a key factor in development and progress of NAFLD. It has been documented
40 that subjects with NAFLD have a e higher level of BMI, and this is associated with the
41 risk of NAFLD[35, 36]. While growing evidence suggested that the determinant of
42 insulin resistance is not the degree of obesity, but the distribution of fat, abdominal fat
43 accumulation is related to insulin resistance[37, 38]. Studies have also shown that in
44 obese adolescents 2-h glucose and insulin resistance are significantly increased with
45 higher visceral fat than those with lower abdominal fat [39, 40]. Central obesity can
46 lead to inflammatory, oxidative stress and metabolic disorders, which are related to the
47 development of insulin resistance[41, 42]. In this study, WHtR, an indicator of central
48 obesity, was associated with NAFLD and the effect was mediated by TyG index among
49 the study participants. This could be that central obesity leads to an increase in the TyG
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 index and thus results in NAFLD.

5
6 The major strength of this study was a large sample size retrospective cohort study
7
8 which included 46,693 aged more than 60 years old. It is believed a cohort study could
9
10 better reflect the real relationship between TyG index and NAFLD. Moreover, we
11
12 established a nonlinear relationship between TyG index and NAFLD using cubic spline
13
14 graph analysis, furthermore, TyG index played a mediation effect between WHtR and
15
16 NAFLD in this study. However, there were several limitations in this study. First, the
17
18 diagnosis of NAFLD was based on the results of abdominal ultrasound instead of liver
19
20 biopsy which only provided information on whether there was the presence of NAFLD.
21
22 Since it is difficult to find mild steatosis by ultrasonography, the incidence of NAFLD
23
24 could be underestimated[31, 43]. Further, the subjects could not provide their history
25
26 of lipid-lowering therapy or antidiabetic drugs as they were elder therefore, information
27
28 about therapy was missing in the data. Additionally, we could not evaluate the
29
30 relationship between TyG index and different NAFLD severity. Also, we lacked other
31
32 more accurately index which can reflect the abdominal obesity status. Even though we
33
34 used WHtR to indicate the abdominal obesity, we were unable to assess a more
35
36 accurately visceral fat index and the prevalence of NAFLD.

37
38 In conclusion, high baseline level of TyG index is significantly associated with a higher
39
40 risk of NAFLD. In addition, TyG index plays a partial mediating role in the relationship
41
42 between WHtR and NAFLD. Our results suggest that it has important clinical meanings
43
44 for monitoring TyG index to prevent NAFLD.

45 **Acknowledgements:**

46
47 This research was funded by the National Natural Science Foundation of China (Grant
48
49 No. 81673165), the National Key Research and Development Programme of China
50
51 (Grant Nos 2017YFC1307705 and 2016YFC0106907). In addition, the authors are
52
53 grateful to Junxing Fan for helping with the quality control of the data. The funders had
54
55 no role in the study design, data collection and analysis, decision to publish, or
56
57 preparation of the manuscript.

58 **Author Contributions:**

1
2
3
4 H.C. and Q.L. designed the study. H.C., S.L., B.Y., X.C., Z.S., W.G and J.H.
5 participated in the data collection and analysis. H.C. and A.A. drafted this manuscript,
6 H.C. S.L. and S.S. interpreted the data. S.S and Q.L. reviewed and revised this
7 manuscript. All authors approved the final manuscript.
8
9
10

11 **Financial support:**

12
13
14 This research was funded by the National Natural Science Foundation of China (Grant
15 No. 81673165), the National Key Research and Development Programme of China
16 (Grant Nos 2017YFC1307705 and 2016YFC0106907)
17
18
19
20
21
22

23 **Conflict of Interest:**

24 All authors have no conflicts of interest.
25

26
27 **Patient and public involvement:** Participants were not involved in the
28 recruitment and conduct of the study
29

30
31 **Patient consent for publication:** Given the retrospective nature of the research,
32 the requirement for informed consent was waived. Patients were not involved in the
33 recruitment and conduct of the study. The study protocol was approved by ethics
34 committee of Zhengzhou University in China.
35
36
37
38

39 **Ethics approval:**

40
41 The study protocol was approved by ethics committee of Zhengzhou University in
42 China (approval number: ZZURIB202004). Given the retrospective nature of the
43 research, the requirement for informed consent was waived.
44
45
46
47

48 **Provenance and peer review:** Not commissioned; externally peer reviewed
49

50
51 **Data availability statement:** The datasets generated and/or analyzed during the
52 current study are available upon request.
53
54

55
56 **Open access:** This is an open access article distributed in accordance with the
57 Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
58 permits others to distribute, remix, adapt, build upon this work non-commercially, and
59
60

license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

References

- (1) Finck BN. Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis. *Diabetes*. 2018;67:2485-93.
- (2) Yu Y, Cai JJ, She ZG, et al. Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases. *Adv Sci*. 2019;6.
- (3) Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology*. 2019;156:1264-+.
- (4) Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. *Nat Rev Gastroenterol Hepatol*. 2013;10:330-44.
- (5) Schindhelm RK, Heine RJ, Diamant M. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. *Diabetes Care*. 2007;30:e94; author reply e5.
- (6) Goldberg D, Ditah IC, Saeian K, et al. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. *Gastroenterology*. 2017;152:1090-+.
- (7) Watt MJ, Miotto PM, De Nardo W, et al. The liver as an endocrine organ - linking NAFLD and insulin resistance. *Endocr Rev*. 2019.
- (8) Baratta F, Pastori D, Polimeni L, et al. Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance. *American Journal of Gastroenterology*. 2017;112:1832-9.
- (9) Fedchuk L, Nascimbeni F, Pais R, et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. *Alimentary Pharmacology & Therapeutics*. 2014;40:1209-22.
- (10) Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. *Nat Rev Gastro Hepat*. 2019;16:377-86.
- (11) Du T, Yuan G, Zhang M, et al. Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance. *Cardiovasc Diabetol*. 2014;13:146.
- (12) Nor NSM, Lee S, Bacha F, et al. Triglyceride glucose index as a surrogate measure of insulin sensitivity in obese adolescents with normoglycemia, prediabetes, and type 2 diabetes mellitus: comparison with the hyperinsulinemic-euglycemic clamp. *Pediatr Diabetes*. 2016;17:458-65.
- (13) Kitae A, Hashimoto Y, Hamaguchi M, et al. The Triglyceride and Glucose Index Is a Predictor of Incident Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. *Can J Gastroenterol Hepatol*. 2019;2019:5121574.
- (14) Khoury M, Manlhiot C, McCrindle BW. Role of the Waist/Height Ratio in the Cardiometabolic Risk Assessment of Children Classified by Body Mass Index. *J Am Coll Cardiol*. 2013;62:742-51.
- (15) Xi B, Mi J, Zhao M, et al. Trends in abdominal obesity among U.S. children and adolescents. *Pediatrics*. 2014;134:e334-9.
- (16) Huang X, Wang QY, Liu TT, et al. Body fat indices as effective predictors of insulin resistance in

- 1
2
3 obese/non-obese polycystic ovary syndrome women in the Southwest of China. *Endocrine*. 2019;65:81-5.
- 4 (17) Motamed N, Rabiee B, Hemasi GR, et al. Body Roundness Index and Waist-to-Height Ratio are
5 Strongly Associated With Non-Alcoholic Fatty Liver Disease: A Population-Based Study. *Hepat Mon*.
6 2016;16:e39575.
- 7
8 (18) Zheng RD, Chen ZR, Chen JN, et al. Role of Body Mass Index, Waist-to-Height and Waist-to-Hip
9 Ratio in Prediction of Nonalcoholic Fatty Liver Disease. *Gastroenterol Res Pract*. 2012;2012:362147.
- 10 (19) Zhang X, Wan Y, Zhang S, et al. Nonalcoholic fatty liver disease prevalence in urban school-aged
11 children and adolescents from the Yangtze River delta region: a cross-sectional study. *Asia Pac J Clin*
12 *Nutr*. 2015;24:281-8.
- 13 (20) Ramirez-Velez R, Izquierdo M, Correa-Bautista JE, et al. Grip Strength Moderates the Association
14 between Anthropometric and Body Composition Indicators and Liver Fat in Youth with an Excess of
15 Adiposity. *J Clin Med*. 2018;7.
- 16 (21) Lin MS, Lin TH, Guo SE, et al. Waist-to-height ratio is a useful index for nonalcoholic fatty liver
17 disease in children and adolescents: a secondary data analysis. *Bmc Public Health*. 2017;17.
- 18 (22) Procino F, Misciagna G, Veronese N, et al. Reducing NAFLD-screening time: A comparative study
19 of eight diagnostic methods offering an alternative to ultrasound scans. *Liver Int*. 2019;39:187-96.
- 20 (23) Kojima S, Watanabe N, Numata M, et al. Increase in the prevalence of fatty liver in Japan over the
21 past 12 years: analysis of clinical background. *J Gastroenterol*. 2003;38:954-61.
- 22 (24) Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in public
23 health research. *Stat Med*. 2010;29:1037-57.
- 24 (25) Jang EH, Chang Y, Ryu S, et al. Cardiovascular Health Metrics in the Development and Regression
25 of Nonalcoholic Fatty Liver Disease: A Cohort Study. *J Clin Med*. 2019;8.
- 26 (26) Petta S, Eslam M, Valenti L, et al. Metabolic syndrome and severity of fibrosis in nonalcoholic fatty
27 liver disease: An age-dependent risk profiling study. *Liver Int*. 2017;37:1389-96.
- 28 (27) Khan RS, Bril F, Cusi K, et al. Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease.
29 *Hepatology (Baltimore, Md)*. 2018.
- 30 (28) Sung KC, Lee MY, Lee JY, et al. Natural course of fatty liver in 36,195 South Korean adults.
31 *Scientific reports*. 2019;9:9062.
- 32 (29) Ballestri S, Nascimbeni F, Romagnoli D, et al. Type 2 Diabetes in Non-Alcoholic Fatty Liver
33 Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight. *Int J Mol Sci*.
34 2016;17:355.
- 35 (30) Sookoian S, Pirola CJ. Systematic review with meta-analysis: risk factors for non-alcoholic fatty
36 liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese
37 patients. *Aliment Pharmacol Ther*. 2017;46:85-95.
- 38 (31) Wong VWS, Chan WK, Chitturi S, et al. Asia-Pacific Working Party on Non-alcoholic Fatty Liver
39 Disease guidelines 2017Part 1: Definition, risk factors and assessment. *J Gastroen Hepatol*. 2018;33:70-
40 85.
- 41 (32) Gastaldelli A. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?
42 *Clin Sci*. 2017;131:2701-4.
- 43 (33) Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. *Cell*
44 *Metab*. 2012;15:635-45.
- 45 (34) Baeck C, Wehr A, Karlmark KR, et al. Pharmacological inhibition of the chemokine CCL2 (MCP-
46 1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. *Gut*.
47 2012;61:416-26.
- 48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 (35) Tang ZL, Pham M, Hao YM, et al. Sex, Age, and BMI Modulate the Association of Physical
4 Examinations and Blood Biochemistry Parameters and NAFLD: A Retrospective Study on 1994 Cases
5 Observed at Shuguang Hospital, China. *BioMed research international*. 2019.
6
7 (36) Liu M, Wang J, Zeng J, et al. Association of NAFLD With Diabetes and the Impact of BMI Changes:
8 A 5-Year Cohort Study Based on 18,507 Elderly. *J Clin Endocrinol Metab*. 2017;102:1309-16.
9
10 (37) Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. *N Engl J*
11 *Med*. 2014;371:1131-41.
12
13 (38) Caprio S, Perry R, Kursawe R. Adolescent Obesity and Insulin Resistance: Roles of Ectopic Fat
14 Accumulation and Adipose Inflammation. *Gastroenterology*. 2017;152:1638-46.
15
16 (39) Taksali SE, Caprio S, Dziura J, et al. High visceral and low abdominal subcutaneous fat stores in
17 the obese adolescent: a determinant of an adverse metabolic phenotype. *Diabetes*. 2008;57:367-71.
18
19 (40) D'Adamo E, Cali AM, Weiss R, et al. Central role of fatty liver in the pathogenesis of insulin
20 resistance in obese adolescents. *Diabetes Care*. 2010;33:1817-22.
21
22 (41) Kursawe R, Dixit VD, Scherer PE, et al. A Role of the Inflammasome in the Low Storage Capacity
23 of the Abdominal Subcutaneous Adipose Tissue in Obese Adolescents. *Diabetes*. 2016;65:610-8.
24
25 (42) Stienstra R, van Diepen JA, Tack CJ, et al. Inflammasome is a central player in the induction of
26 obesity and insulin resistance. *P Natl Acad Sci USA*. 2011;108:15324-9.
27
28 (43) Wong VW, Adams LA, de Ledinghen V, et al. Noninvasive biomarkers in NAFLD and NASH -
29 current progress and future promise. *Nat Rev Gastroenterol Hepatol*. 2018;15:461-78.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1 ROC curve of TyG on NAFLD

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2 ROC curve of TyG on NAFLD
152x110mm (300 x 300 DPI)




Figure 3 Restricted cubic spline graph of risk of TyG index and the development of NAFLD.

123x90mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4 The mediate effect of TyG index on WHtR and NAFLD.

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	1,2 2,3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3,4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4,5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	4,5 N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4,5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4,5
Bias	9	Describe any efforts to address potential sources of bias	N/A
Study size	10	Explain how the study size was arrived at	4
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5,6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	5,6 N/A N/A N/A N/A
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	6,7 N/A 4
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	6,7 N/A 6
Outcome data	15*	Report numbers of outcome events or summary measures over time	6,7

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7,8
2			(b) Report category boundaries when continuous variables were categorized	7,8
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
4				
5				
6				
7				
8				
9	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
10				
11	Discussion			
12				
13	Key results	18	Summarise key results with reference to study objectives	10
14	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12
15				
16	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10,11,12
17				
18				
19	Generalisability	21	Discuss the generalisability (external validity) of the study results	12
20				
21	Other information			
22	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13
23				
24				

25
26 *Give information separately for exposed and unexposed groups.

27
28 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and
29 published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely
30 available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at
31 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is
32 available at <http://www.strobe-statement.org>.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Relationship between triglyceride glucose index and the incidence of nonalcoholic fatty liver disease in the elderly: a retrospective cohort study in China

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-039804.R2
Article Type:	Original research
Date Submitted by the Author:	08-Aug-2020
Complete List of Authors:	Chen, Huanan; Zhengzhou University, Department of Nutrition and Food Hygiene, College of Public Health Li, Sangsang; Xinyang Central Hospital, Medical record room Amoah, Adwoa Nyantakyiwaa ; Zhengzhou University, Department of Nutrition and Food Hygiene, College of Public Health Bo, Yacong; The Chinese University of Hong Kong, Jockey Club School of Public Health and Primary Care Chen, Xuejiao; Zhengzhou University, Department of Social Medicine, College of Public Health Shi, Zhan; Henan University of Traditional Chinese Medicine, Department of Pharmacy, Zhengzhou People's Hospital Wan, Guodong; Henan Province Health and Family Planning Commission, Health Commission of Xinzheng Huang, Jian; Henan Province Center for Disease Control and Prevention, Henan Province Center for Disease Control and Prevention shi, songhe; Zhengzhou University, Department of Epidemiology and Biostatistics Lyu, Qianjun ; Zhengzhou University, Department of Nutrition and Food Hygiene, College of Public Health; Zhengzhou University, Department of Nutrition, The First Affiliated Hospital of Zhengzhou University
Primary Subject Heading:	Gastroenterology and hepatology
Secondary Subject Heading:	Gastroenterology and hepatology
Keywords:	Hepatobiliary disease < GASTROENTEROLOGY, Lipid disorders < DIABETES & ENDOCRINOLOGY, PUBLIC HEALTH

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Relationship between triglyceride glucose index and the incidence of nonalcoholic fatty liver disease in the elderly: a retrospective cohort study in China

Chen Huanan¹, Li Sangsang², Amoah, Adwoa Nyantakyiwaa¹, Bo Yacong³ Chen Xuejiao⁴, Shi Zhan⁵, Wan Guodong⁶, Huang Jian⁷, Shi Songhe⁸, Lyu Qianjun^{1,9}.

1. Department of Nutrition and Food Hygiene, College of Public Health, Zhengzhou University, Zhengzhou, Henan, P.R. China.
2. Medical record room, Xinyang Central Hospital, Xinyang, Henan, P.R. China.
3. Jockey Club School of Public Health and Primary Care, the Chinese University of Hong Kong
4. Department of Social Medicine, College of Public Health, Zhengzhou University, Zhengzhou, Henan, P.R. China.
5. Department of Pharmacy, Zhengzhou People's Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, P.R. China.
6. Health Commission of Xinzheng, Henan Province Health and Family Planning Commission, Henan, P.R. China.
7. Central for Disease Control of Xinzheng, Henan Province Center for Disease Control and Prevention, Henan, P.R. China.
8. Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, P.R. China.
9. Department of Nutrition, The First Affiliated Hospital of Zhengzhou University, Henan, P.R. China

Corresponding Authors:

Qianjun Lyu, PhD, Department of Nutrition and Food Hygiene, College of Public Health, Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, 100 Science Road, Zhengzhou, China. Phone: (0371) 67781923, email: lqjnutr@zzu.edu.cn.

Songhe Shi, PhD, Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, 100 Science Road, Zhengzhou, China. Phone:(0371)

67781254, email: zzussh@126.com.

Abstracts

Objective: Nonalcoholic fatty liver disease (NAFLD) is one of the major causes of liver-related diseases but relationship between triglyceride glucose (TyG) and NAFLD in the elderly is not reported yet. In this study, we investigated the role of TyG index for predicting the incidence of NAFLD in the elderly.

Design and setting : This is a prospective cohort study in Henan, China, from 2011-2018.

Participants and Methods : In total, 46,693 elderly who participated in a routine physical examination programme from 2011 to 2018 were included in this study. TyG index was calculated as \ln [fasting triglyceride (mg/dl) \times fasting plasma glucose (mg/dl)/2], while NAFLD was defined as hepatic steatosis after excluding other causes based on the results of abdominal ultrasonography; Cox regression model was performed to explore the relationship between TyG index and NAFLD. Also, mediation effect was used to analyze the role of the TyG index in WHtR and NAFLD.

Results: During the 149041.50 person-years follow-up, a total of 5660 NAFLD events occurred (3.80/100 person-years). After adjusting for potential confounding factors, quartiles 4 of TyG index significantly increased the incidence of NAFLD compared with quartile 1, the hazard ratios (HRs) and 95% confidence intervals (CI) were 1.314(1.234,1.457). In addition, TyG index played a partial mediating role in the relationship between WHtR and NAFLD and indirect effect was 1.009(1.006,1.011).

Conclusion: Higher TyG index was associated with higher risk of NAFLD in the aged and therefore, TyG index may be a novel predictor for incidence of NAFLD. Further, regular examination and evaluation of the TyG index might be useful for controlling the occurrence of NAFLD.

Key words: Nonalcoholic fatty liver disease; Triglyceride glucose index; Waist-to-height ratio; Mediation effect.

Strengths and limitations of this study :

1
2
3
4 Data for this cohort study were retrieved from a large regular physical examination in
5 Henan, China.

6
7 Restricted cubic spline analysis and mediation effect were used in this study, which can
8 reflect the relationship between TyG index and NAFLD more realistically.

9
10 The sample size and statistical power were sufficient in this study.

11
12 The severity of disease in this cohort study was not available when data were retrieved.
13 Some participants were excluded in this study because they did not have abdominal
14 ultrasound testing.

15 16 17 18 **Introduction**

19
20 Nonalcoholic fatty liver disease(NAFLD) encompasses a series of spectrum of liver
21 diseases, ranging from simple steatosis, nonalcoholic steatohepatitis, cirrhosis to
22 hepatocellular carcinoma[1]. With the change of lifestyle and increase of obesity,
23 NAFLD currently exceeds viral hepatitis and is becoming the most common chronic
24 liver disease, affecting about a quarter of the common population in the world[2, 3].
25 NAFLD is one of the major causes of liver-related disease such as cirrhosis,
26 hepatocellular carcinoma and liver transplantation. Moreover, NAFLD is also
27 associated with higher prevalence and incidence of cardiovascular disease such as
28 coronary, cerebrovascular and peripheral vascular disease [4, 5]. In the next decade,
29 NAFLD is expected to become the leading cause for liver transplantation in the United
30 States instead of hepatitis C[6].

31
32 The development of NAFLD is a complex process involving genetic and environmental
33 factors. As an organ of metabolism, the disorder of glucose and lipid metabolism plays
34 an important role in the progress of NAFLD[7]. Several studies found that IR could
35 increase the risk of NAFLD even without the existence of T2DM and IR may be the
36 genesis of steatosis[7-10].Furthermore, as an early marker of IR, TyG has been
37 proposed to be an inexpensive and reliable surrogate to IR[11, 12] Yet researches about
38 the relationship between TyG index and the risk of NAFLD are limited [9, 13].
39 Additionally, as far as we know, the association between TyG index and the incidence
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

of NAFLD in the older has not been reported.

WHtR is a maker of abdominal obesity and studies have also reported that WHtR is related to IR[14, 15] and also the higher risk of NAFLD [16-22]. Whether there is an existing effect of TyG index on the relationship between WHtR and NAFLD and how it affects NAFLD is still unclear. This retrospective cohort study therefore sought to explore the relationship between baseline level of TyG index and the incidence of NAFLD.

1.Participants and methods

1.1 Subjects:

We retrospectively analyzed the 99,997 subjects who had the data of liver ultrasonography, fasting triglyceride as well as fasting plasma glucose in physical examination programme in Xinzheng, Henan Province, in Central China City from January 2011 to December 2018. This physical examination programme was for the local residents over 60 years old and was supported by the government of Xinzheng, Henan Province in China. Individuals with any of the following criteria were excluded:1) missing follow-up; 2) subjects with NAFLD at baseline;3) subjects with hepatitis B or C virus or had the history of excess alcohol intake (the threshold for women <20 g/d and <30 g/d for men). A total of 46,693 eligible participants were included in this cohort study (**Figure 1**). The datasets generated and/or analyzed during the current study are available upon request. Given the retrospective nature of the research, the requirement for informed consent was waived. Patients were not involved in the recruitment and conduct of the study. The study protocol was approved by ethics committee of Zhengzhou University in China (Approve number: ZZURIB202004).

Figure 1 Flow chart for participants exclusions performed

1.2 Data collection

Demographic data and clinical information of the subjects were collected when they underwent health check-up. Demographic data included age, sex, excess alcohol intake

(yes/no), current smoking status (yes/no), lives alone(yes/no) and exercises regularly(yes/no). The definition of current smoking was that subjects used to smoke 100 cigarettes or above in their lifetime, and now is still smoking regularly. Excessive drinking was defined as drinking more than 30g /d for men and 20g/d for women. Exercising regularly was defined as more than 3 times a week, and 30 minutes moderate intensity exercise each time. The clinic records included anthropometric measurements (such as height, weight, blood pressure, waist circumference) and laboratory data. Height measurement required the subjects without shoes, stand straight on the ground, and their hips and heels against the wall, to measure the weight, the participants were without shoes and wore light clothing. Blood pressure of the subjects in a sitting position after 5 minutes of rest was measured twice by an electronic sphygmomanometer (Omron HEM-7125, Kyoto, Japan), and the mean value of the two measurements was recorded. Waist circumference was measured at the midpoint of the distance between the lowest costal ridge and the upper border of the iliac crest. After fasting for 8 hours, the blood samples of subjects were collected to determine the level of fasting plasma glucose (FPG), total cholesterol (TC) and triglyceride (TG) using a biochemical detector (DIRUI CS380, Changchun, China). Alanine aminotransferase (ALT), aspartate transaminase (AST) and total bilirubin (TB) was detected by (DIRUI CS380, Changchun, China). The TyG index were calculated as the \ln [fasting TG (mg/dl) \times FPG (mg/dl)/2]. WHtR was defined as waist circumference(cm)/height(cm).

1.3 NAFLD definition

All participants of this study underwent liver ultrasonography (SIUI CZXL-38G, Shantou, China). The results of ultrasound prompted the existence of steatohepatitis: enhanced liver echogenicity, echogenicity greater in liver than kidneys, deep attenuation and vascular blurring[23] and after excluding the steatohepatitis caused by alcohol, viruses and drugs was defined as NAFLD. All ultrasound examinations were performed by an experienced professional radiologist.

1.4 Statistics

Categorical variables were showed as proportions while continuous variables were

presented as means \pm standard deviation (SD) or median (interquartile range) (IQR). ANOVA/two - paired sample t tests (continuous variables, normal distribution) and chi-square tests (categorical variables) were used to compare the difference in different groups. Logistic regression for categorical variables and linear regression for continuous variables were used to obtain the *P* value for trend.

Cox regression models were used to explore the relationship between TyG index and the incidence of NAFLD, the lowest quartiles of TyG index was defined as the reference. Hazards ratio (*HR*) and confidence interval (*CI*) of NAFLD in quartiles and continuous were expressed in separate models. To assess the relationship across increasing quartiles, *P* value for trend tests were used by entering median value in each quartile in Cox regression models.

AUCs were used to evaluate the ability of the baseline TyG index to predict the risk of NAFLD. Restricted cubic spline models were used to explore whether there was a nonlinear relationship between continuous and occurrence of NAFLD [24]. Mediation analysis used a Cox regression to study the mediate effect of TyG index between WHtR and NAFLD.

Mediation analysis was conducted using R version 3.5.0 (R Foundation for Statistical Computing, Vienna, Austria), and Restricted cubic spline were performed in Stata v 12.0 (Stata Corp, College Station, TX, USA). The other analyses were performed by SPSS software, version 21.0 (SPSS Inc, Chicago). Probability values for statistical tests, where two-tailed *P*-values < 0.05 were regarded as significant.

2. Result

2.1 Baseline Characteristics of included subjects

A total of 46,693 subjects were included in this study. The baseline characteristics of included participants based on follow-up were presented in **Table 1**. The mean age of subjects was 68.91 (7.17) and 48.89% were men. The average follow-up was 3.19(1.52) years, during the 149041 person-years follow-up, 5660 subjects occurred NAFLD (3.80/100 person-years). Subjects with NAFLD with higher BMI, WHtR, TC, FBG, DBP, SBP, ALT, and TB and the incidence of NAFLD was higher in younger, current

smoking, regular exercise, with diabetes and hypertension but the baseline level of AST had no association with the incidence of NAFLD.

Table 1 baseline characteristics of included subjects according to the follow-up outcome

variables	No NAFLD (n=41033)	NAFLD (n=5660)	P value
Men, n (%) †	20799(50.69)	2033(35.92)	<0.001
Age (years) ‡	69.18±7.27	66.93±6.00	<0.001
Current smoking, n (%) †	6846 (16.70)	594(10.51)	<0.001
Exercise, n (%) †	7865(19.22)	1131(20.02)	<0.001
Live alone, n (%) †	8772(21.38)	1015(17.93)	<0.001
Diabetes, n (%) †	5554(13.54)	1344(23.75)	<0.001
Hypertension, n (%) †	15945 (38.86)	2952(52.16)	<0.001
WHtR‡	0.51±0.06	0.54±0.07	<0.001
BMI‡	23.62±2.85	26.02±3.10	<0.001
SBP (mmHg) ‡	132.62±19.38	135.32±19.76	<0.001
DBP (mmHg) ‡	78.92±10.34	80.91±10.33	<0.001
FPG (mmol/L) §	5.20(4.70-5.70)	5.30(4.80-5.93)	<0.001
TC (mmol/L) §	4.59(4.01-5.21)	4.69(4.09-5.38)	<0.001
TG (mmol/L) §	1.10(0.81-1.47)	1.28(0.90-1.77)	<0.001
TB (µmol/L) §	11.51(8.60-14.10)	11.30(8.30-13.80)	<0.001
ALT(U/L) §	18.00(13.00-24.50)	18.60(14.00-25.00)	<0.001
AST(U/L) §	21.80(16.89-26.90)	21.90(16.89-27.00)	0.892
TyG‡	8.43±0.54	8.61±0.59	<0.001

†: n (%); ‡: mean (SD); §: median (IQR)

Abbreviations: BMI, body mass index; WHtR, waist-to-height ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; TC, triglycerides; TG, triglyceride; TB, total bilirubin; ALT, alanine aminotransferase, AST, aspartate aminotransferase; TyG, triglyceride glucose.

2.2 Association between TyG index and NAFLD

The relationship between TyG index and the incidence of NAFLD were showed in **Table 2**. Compared with quartile 1 of TyG index, the hazard ratio (HR) and its corresponding 95% confidence interval (CI) for quartile2, quartile3, and quartile 4 were 1.056(0.971,1.149), 1.300(1.200,1.408) and 1.972(1.832,2.123), respectively. Risk for NAFLD was significantly higher with increasing quartiles of TyG for the *P* value of trend of linearity <0.001. In addition, even after adjusted possible confounding factors, the risk of quartile 3 of TyG index (1.314(1.234,1.457)) on the incidence of NAFLD still existed. In order to further verify the relationship between the TyG index and the

incidence of NAFLD, TyG index was used as continuous variables for the above analysis and the results also proved that higher level of TyG increased the risk of NAFLD (1.265(1.200,1.334)), even after adjusted possible confounding factors. These results proved that the baseline level of TyG was associated with the risk of NAFLD, thus the higher the TyG level, the higher incidence of NAFLD.

Since the majority of the subjects could not respond on their history of lipid-lowering therapy or antidiabetic drugs, we failed to access information about therapy. Sensitivity analysis (n=37428) was executed after excluding subjects with diabetes, CVD and stroke, who might take medicine that affects level of FPG and TG. The results of sensitivity analysis (Suppl table 1) also suggested that higher level of TyG significantly increased the incidence of NAFLD, which were similar with the findings in total population.

Table 2 relationship between TyG index and the risk of NAFLD

	N	TyG index		
		unadjusted	Model 1	Model 2
As continuous	50037	1.697(1.619,1.779)	1.577(1.504,1.653)	1.265(1.200,1.334)
Quartile 1	12556	Reference	Reference	Reference
Quartile 2	12458	1.056(0.971,1.149)	1.035 (0.951,1.126)	0.980(0.895,1.073)
Quartile 3	12522	1.300(1.200,1.408)	1.259(1.162,1.364)	1.090(0.999,1.190)
Quartile 4	12501	1.972(1.832,2.123)	1.783(1.655,1.920)	1.314(1.234,1.457)
<i>P</i> for trend		<0.001	<0.001	<0.001

Quartile 1≤8.11; 8.12<Quartile 2≤8.44; 8.45<Quartile 3≤8.78; 8.79<Quartile 4

Model 1: adjusted age and sex;

Model 2: model 1 plus living alone, current smoking, exercise, waist-to-height ratio, systolic blood pressure, diastolic blood pressure, alanine aminotransferase, aspartate aminotransferase, total bilirubin, total cholesterol and diabetes.

2.3 The ability of TyG to predict NAFLD

The receiver operating characteristic curves (ROC) were used to evaluate the ability of baseline level of TyG to predict the development of NAFLD. The best cutoff value for TyG index to diagnosis NAFLD was 8.63, and its corresponding area under the receiver operating characteristic curves (AUCs) was 0.60 (95%CI:0.58,0.61), showed in **Figure 2A**. Subgroup analysis was performed to further analyze the influence of sex on ability

of TyG index to predict incident NAFLD, the best cutoff value for men (8.68) was lower in men than women (8.75), and corresponding AUCs was 0.587 (95%CI:0.573-0.600) for men and 0.584 (95%CI:0.573-0.594) for men, respectively(**Figure 2B and 2C**).

Figure 2 ROC curve of TyG on NAFLD

Receiver operating characteristics (ROC) curves for baseline TyG to predict incident NAFLD among 60 years old or older. TyG, triglyceride glucose; NAFLD, nonalcoholic fatty liver diseases.

2.4 Restricted cubic spline analysis to evaluate the relationship between TyG and NAFLD

In order to further explore the relationship between TyG and the risk of NAFLD, restricted cubic spline graph was used to analyze the dose-response relationship between TyG and the incidence of NAFLD. As shown in **Figure 3A**, there was a nonlinear relationship between level of TyG index and the risk of NAFLD based on the adjusted Cox regression model. This result proved again that higher level of TyG was associated with higher incidence of NAFLD. Subgroup analyses also found that there was a nonlinear relationship between TyG index and incident NAFLD both in men and women (**Figure 3B and C**).

Figure 3 Restricted cubic spline graph of risk of TyG index and the development of NAFLD.

Multivariate adjusted hazard ratios of NAFLD increased during follow-up when the baseline level of TyG index was 8.63 and above. Adjusted variables including age, sex (not for sex subgroup analysis), living alone, current smoking, exercise, waist-to-height ratio, systolic blood pressure, diastolic blood pressure, alanine aminotransferase, aspartate aminotransferase, total bilirubin, total cholesterol. TyG, triglyceride glucose; NAFLD, nonalcoholic fatty liver diseases; CI, confidence interval.

2.5 Mediation effects

In previous analysis we found that WHtR was associated with the incidence of NAFLD, what's more, WHtR was also associated with TyG index ($P < 0.05$, and the data wasn't

shown). If WHtR would lead to IR and TyG index was a reliable and cheap surrogate indicate for IR, then there might be a mediating effect of TyG index between WHtR and NAFLD. Therefore, mediation analysis was used to confirm whether there was a mediating effect and to what extent TyG index affect the relationship between WHtR and NAFLD. Results (presented in **Table 3 and Figure 4**) of mediation analysis revealed that the total effect of WHtR on NAFLD was 1.476 (1.437,1.517) and the direct effect was 1.463(1.842,1.950). Therefore, TyG index played a partial role and the indirect effect was 1.019 (1.006,1.011). This result may indicate that abdominal obesity may lead to disorders of glycolipid dyslipidemia which can lead to an increase of the TyG index.

Table 3 Mediation analysis of the relationship between TyG index and NAFLD by WHtR

Effect	HR (95%CI)
Total effect	1.476 (1.437,1.517)
Direct effect	1.463 (1.842,1.950)
Indirect effect	1.009(1.006,1.011)

Figure 4 The mediate effect of TyG index on WHtR and NAFLD.

The effect of WHtR on NAFLD was mediated by baseline level TyG index by adjusted potential confounders namely age, sex, living alone, current smoking, exercise, systolic blood pressure, diastolic blood pressure, alanine aminotransferase, aspartate aminotransferase, total bilirubin, total cholesterol.

3. Discussion

With the acceleration of the aging process, the health in the elderly has gradually become an important issue in the society. NAFLD, a common liver disease in China, also has become one of the main health problems of the elderly. Although there were some studies about TyG index and NAFLD, research about TyG index and the incidence of NAFLD in the older adults has not been reported.

In this retrospective cohort study, we found the incidence of NAFLD was 3.80/100 person-years among the elderly over 60, which was lower than a cohort study of Korea

1
2
3
4 (the incidence of NAFLD was 4.84/100 person-years)[25]. Probably, the age of the
5 subjects in the Korean cohort study(mean age was 36.1) was younger than ours and age
6 could affect the prevalence and severity of NAFLD[26]. Additionally, the incidence of
7 NAFLD decreased as the age increased in this study and the $P_{\text{value for trend}} < 0.001$ (data
8 not presented in this research). A retrospective cohort study on TyG index and NAFLD
9 in Japan also found that higher TyG was associated with higher risk of NAFLD, which
10 was consistent with our results[13]. As far as we know, this research is the first study
11 to focus on the effect of TyG index on the incidence of NAFLD in the elderly in China.
12 Our study also reported the relationship between TyG index was nonlinear hence the
13 incidence of NAFLD would increase significantly when TyG is above 8.63.
14 Furthermore, the results of the mediation effect suggested that TyG index was not an
15 independent factor for the development of NAFLD, but a partial mediator between
16 WHtR and NAFLD.
17

18
19 The results of ROC suggested that 8.63 was the best cutoff value of TyG index for
20 predicting the incidence of NAFLD. while, the cut off value TyG index was higher than
21 Simental-Mendía LE et.al[27],which might be caused by the following reasons. Firstly,
22 the participants were different between two studies, in Simental-Mendía LE et.al
23 research, the participants were from asymptomatic women aged 20 to 65 years in
24 Mexico, while in our study, the participants were 60 or older from China (including
25 men and women), moreover, the cutoff value in our research was similar to several
26 studies from Asia[13, 28, 29]; Secondly, study design of Simental-Mendía LE et.al is
27 different from ours; What's more, the methods to diagnosis NAFLD were different;
28 Additionally, the mean values of TyG index were different. The above might be the
29 reasons that resulted in different cutoff value. TyG index is an inexpensive and reliable
30 surrogate index for IR and plays an important role in the development and progression
31 of NAFLD. Consequently, even in the absence of diabetes, IR can lead to changes from
32 normal liver to NAFL to NASH[10]. Various studies have confirmed that IR is closely
33 related to the occurrence and development of NAFLD[30-33].
34

35
36 The mechanism of IR on NAFLD could be explained by the following reasons. On one
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 hand, IR has a direct effect on metabolism of glucose and participates in the occurrence
5 and development of NAFLD by disturbing the glucose and lipid metabolism disorder
6 of the liver[30]. Insulin resistance reduces glucose uptake in the adipose tissues and
7 muscles while the hydrolysis of triglycerides in adipose tissue as well increases the
8 conversion of glucose to fatty acids in the liver. Moreover, IR could also increase de
9 novo lipogenesis by activating sterol regulatory element binding protein (SREBP1).
10 High insulin levels can increase the uptake of free fatty acids in the liver and the
11 synthesis of TG, causing excessive accumulation of fat in the liver, which could
12 initiate steatosis and then lead to the occurrence of NAFLD[7, 34, 35]. On the other
13 hand, IR is always linked to chronic mild inflammation by releasing inflammatory
14 factors such as TNF α , IL-6, IL-1 and monocyte chemoattractant protein-1, immune
15 cells or adipocytes which can in turn promote IR and participate in the development
16 and progression of NAFLD[36, 37].

17
18
19
20
21
22
23
24
25
26
27
28
29 Obesity is a key factor in development and progress of NAFLD. It has been documented
30 that subjects with NAFLD have a e higher level of BMI, and this is associated with the
31 risk of NAFLD[38, 39]. While growing evidence suggested that the determinant of
32 insulin resistance is not the degree of obesity, but the distribution of fat, abdominal fat
33 accumulation is related to insulin resistance[40, 41]. Studies have also shown that in
34 obese adolescents 2-h glucose and insulin resistance are significantly increased with
35 higher visceral fat than those with lower abdominal fat [42, 43]. Central obesity can
36 lead to inflammatory, oxidative stress and metabolic disorders, which are related to the
37 development of insulin resistance[44, 45]. In this study, WHtR, an indicator of central
38 obesity, was associated with NAFLD and the effect was mediated by TyG index among
39 the study participants. This could be that central obesity leads to an increase in the TyG
40 index and thus results in NAFLD.

41
42
43
44
45
46
47
48
49
50
51
52 The major strength of this study was a large sample size retrospective cohort study
53 which included 46,693 aged more than 60 years old. it is believed a cohort study could
54 better reflect the real relationship between TyG index and NAFLD. Moreover, we
55 established a nonlinear relationship between TyG index and NAFLD using cubic spline

graph analysis, furthermore, TyG index played a mediation effect between WHtR and NAFLD in this study. However, there were several limitations in this study. First, liver biopsy is gold standard to diagnosis NAFLD, while, in this study, we executed abdominal ultrasound to diagnosis NAFLD. While, liver biopsy is unrealistic to screen NAFLD in general population for the prevalence of NAFLD is high. Previous study also found that abdominal ultrasound is less expensive than other advanced imaging methods, and is currently the most widely used imaging tool in clinic and the most acceptable method for the first-line screening of steatosis[46]. Furthermore, the subjects could not provide their history of lipid-lowering therapy or antidiabetic drugs as they were elder therefore, information about therapy was missing in the data. Additionally, we could not evaluate the relationship between TyG index and different NAFLD severity. Also, we lacked other more accurately index which can reflect the abdominal obesity status. Even though we used WHtR to indicate the abdominal obesity, we were unable to assess a more accurately visceral fat index and the prevalence of NAFLD. In conclusion, high baseline level of TyG index is significantly associated with a higher risk of NAFLD. In addition, TyG index plays a partial mediating role in the relationship between WHtR and NAFLD. Our results suggest that it has important clinical meanings for monitoring TyG index to prevent NAFLD.

Acknowledgements:

This research was funded by the National Natural Science Foundation of China (Grant No. 81673165), the National Key Research and Development Programme of China (Grant Nos 2017YFC1307705 and 2016YFC0106907). In addition, the authors are grateful to Junxing Fan for helping with the quality control of the data. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions:

H.C. and Q.L. designed the study. H.C., S.L., B.Y., X.C., Z.S., W.G and J.H. participated in the data collection and analysis. H.C. and A.A. drafted this manuscript,

1
2
3
4 H.C. S.L. and S.S. interpreted the data. S.S and Q.L. reviewed and revised this
5 manuscript. All authors approved the final manuscript.
6

7
8 **Financial support:**
9

10 This research was funded by the National Natural Science Foundation of China (Grant
11 No. 81673165), the National Key Research and Development Programme of China
12 (Grant Nos 2017YFC1307705 and 2016YFC0106907)
13
14
15
16
17
18

19 **Conflict of Interest:**
20

21 All authors have no conflicts of interest.
22

23 **Patient and public involvement:** Participants were not involved in the
24 recruitment and conduct of the study
25

26 **Patient consent for publication:** Given the retrospective nature of the research,
27 the requirement for informed consent was waived. Patients were not involved in the
28 recruitment and conduct of the study. The study protocol was approved by ethics
29 committee of Zhengzhou University in China.
30
31
32
33
34

35 **Ethics approval:**
36

37 The study protocol was approved by ethics committee of Zhengzhou University in
38 China (approval number: ZZURIB202004). Given the retrospective nature of the
39 research, the requirement for informed consent was waived.
40
41
42
43

44 **Provenance and peer review:** Not commissioned; externally peer reviewed
45

46 **Data availability statement:** The datasets generated and/or analyzed during the
47 current study are available upon request.
48
49

50 **Open access:** This is an open access article distributed in accordance with the
51 Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
52 permits others to distribute, remix, adapt, build upon this work non-commercially, and
53 license their derivative works on different terms, provided the original work is properly
54 cited, appropriate credit is given, any changes made indicated and the use is non-
55
56
57
58
59
60

commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

References

- (1) Finck BN. Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis. *Diabetes*. 2018;67:2485-93.
- (2) Yu Y, Cai JJ, She ZG, et al. Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases. *Adv Sci*. 2019;6.
- (3) Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology*. 2019;156:1264-81 e4.
- (4) Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. *Nat Rev Gastroenterol Hepatol*. 2013;10:330-44.
- (5) Schindhelm RK, Heine RJ, Diamant M. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. *Diabetes Care*. 2007;30:e94; author reply e5.
- (6) Goldberg D, Ditah IC, Saeian K, et al. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. *Gastroenterology*. 2017;152:1090-+.
- (7) Watt MJ, Miotto PM, De Nardo W, et al. The liver as an endocrine organ - linking NAFLD and insulin resistance. *Endocr Rev*. 2019.
- (8) Baratta F, Pastori D, Polimeni L, et al. Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance. *American Journal of Gastroenterology*. 2017;112:1832-9.

- 1
2
3
4 (9) Fedchuk L, Nascimbeni F, Pais R, et al. Performance and limitations of steatosis biomarkers
5
6 in patients with nonalcoholic fatty liver disease. *Alimentary Pharmacology & Therapeutics*.
7
8
9 2014;40:1209-22.
10
11 (10) Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. *Nat*
12
13 *Rev Gastro Hepat*. 2019;16:377-86.
14
15
16 (11) Du T, Yuan G, Zhang M, et al. Clinical usefulness of lipid ratios, visceral adiposity indicators,
17
18 and the triglycerides and glucose index as risk markers of insulin resistance. *Cardiovasc*
19
20 *Diabetol*. 2014;13:146.
21
22
23 (12) Nor NSM, Lee S, Bacha F, et al. Triglyceride glucose index as a surrogate measure of
24
25 insulin sensitivity in obese adolescents with normoglycemia, prediabetes, and type 2 diabetes
26
27 mellitus: comparison with the hyperinsulinemic-euglycemic clamp. *Pediatr Diabetes*.
28
29
30 2016;17:458-65.
31
32
33 (13) Kitae A, Hashimoto Y, Hamaguchi M, et al. The Triglyceride and Glucose Index Is a
34
35 Predictor of Incident Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. *Can*
36
37 *J Gastroenterol Hepatol*. 2019;2019:5121574.
38
39
40
41 (14) Khoury M, Manlhiot C, McCrindle BW. Role of the Waist/Height Ratio in the
42
43 Cardiometabolic Risk Assessment of Children Classified by Body Mass Index. *J Am Coll*
44
45 *Cardiol*. 2013;62:742-51.
46
47
48 (15) Xi B, Mi J, Zhao M, et al. Trends in abdominal obesity among U.S. children and adolescents.
49
50
51 *Pediatrics*. 2014;134:e334-9.
52
53
54 (16) Huang X, Wang QY, Liu TT, et al. Body fat indices as effective predictors of insulin
55
56 resistance in obese/non-obese polycystic ovary syndrome women in the Southwest of China.
57
58
59
60

1
2
3
4 Endocrine. 2019;65:81-5.
5

6 (17) Motamed N, Rabiee B, Hemasi GR, et al. Body Roundness Index and Waist-to-Height
7 Ratio are Strongly Associated With Non-Alcoholic Fatty Liver Disease: A Population-Based
8 Study. Hepat Mon. 2016;16:e39575.
9
10
11
12

13 (18) Zheng RD, Chen ZR, Chen JN, et al. Role of Body Mass Index, Waist-to-Height and Waist-
14 to-Hip Ratio in Prediction of Nonalcoholic Fatty Liver Disease. Gastroenterol Res Pract.
15 2012;2012:362147.
16
17
18
19
20

21 (19) Zhang X, Wan Y, Zhang S, et al. Nonalcoholic fatty liver disease prevalence in urban
22 school-aged children and adolescents from the Yangtze River delta region: a cross-sectional
23 study. Asia Pac J Clin Nutr. 2015;24:281-8.
24
25
26
27
28

29 (20) Ramirez-Velez R, Izquierdo M, Correa-Bautista JE, et al. Grip Strength Moderates the
30 Association between Anthropometric and Body Composition Indicators and Liver Fat in Youth
31 with an Excess of Adiposity. J Clin Med. 2018;7.
32
33
34
35
36

37 (21) Lin MS, Lin TH, Guo SE, et al. Waist-to-height ratio is a useful index for nonalcoholic fatty
38 liver disease in children and adolescents: a secondary data analysis. BMC Public Health.
39 2017;17.
40
41
42
43
44

45 (22) Procino F, Misciagna G, Veronese N, et al. Reducing NAFLD-screening time: A
46 comparative study of eight diagnostic methods offering an alternative to ultrasound scans. Liver
47 Int. 2019;39:187-96.
48
49
50
51

52 (23) Kojima S, Watanabe N, Numata M, et al. Increase in the prevalence of fatty liver in Japan
53 over the past 12 years: analysis of clinical background. J Gastroenterol. 2003;38:954-61.
54
55
56
57

58 (24) Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in
59
60

1
2
3
4 public health research. *Stat Med*. 2010;29:1037-57.

5
6 (25) Jang EH, Chang Y, Ryu S, et al. Cardiovascular Health Metrics in the Development and
7
8
9 Regression of Nonalcoholic Fatty Liver Disease: A Cohort Study. *J Clin Med*. 2019;8.

10
11 (26) Petta S, Eslam M, Valenti L, et al. Metabolic syndrome and severity of fibrosis in
12
13
14 nonalcoholic fatty liver disease: An age-dependent risk profiling study. *Liver Int*. 2017;37:1389-
15
16
17 96.

18
19 (27) Simental-Mendia LE, Simental-Mendia E, Rodriguez-Hernandez H, et al. The product of
20
21
22 triglycerides and glucose as biomarker for screening simple steatosis and NASH in
23
24
25 asymptomatic women. *Ann Hepatol*. 2016;15:715-20.

26
27 (28) Zheng R, Du Z, Wang M, et al. A longitudinal epidemiological study on the triglyceride and
28
29
30 glucose index and the incident nonalcoholic fatty liver disease. *Lipids Health Dis*. 2018;17:262.

31
32 (29) Zhang S, Du T, Zhang J, et al. The triglyceride and glucose index (TyG) is an effective
33
34
35 biomarker to identify nonalcoholic fatty liver disease. *Lipids Health Dis*. 2017;16:15.

36
37 (30) Khan RS, Bril F, Cusi K, et al. Modulation of Insulin Resistance in Nonalcoholic Fatty Liver
38
39
40 Disease. *Hepatology (Baltimore, Md)*. 2018.

41
42 (31) Sung KC, Lee MY, Lee JY, et al. Natural course of fatty liver in 36,195 South Korean adults.
43
44
45 *Scientific reports*. 2019;9:9062.

46
47 (32) Ballestri S, Nascimbeni F, Romagnoli D, et al. Type 2 Diabetes in Non-Alcoholic Fatty Liver
48
49
50 Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight. *Int J Mol Sci*.
51
52
53 2016;17:355.

54
55 (33) Sookoian S, Pirola CJ. Systematic review with meta-analysis: risk factors for non-alcoholic
56
57
58 fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean
59
60

1
2
3
4 and obese patients. *Aliment Pharmacol Ther.* 2017;46:85-95.

5
6 (34) Wong VWS, Chan WK, Chitturi S, et al. Asia-Pacific Working Party on Non-alcoholic Fatty
7
8 Liver Disease guidelines 2017Part 1: Definition, risk factors and assessment. *J Gastroen*
9
10
11
12 *Hepatol.* 2018;33:70-85.

13
14 (35) Gastaldelli A. Insulin resistance and reduced metabolic flexibility: cause or consequence
15
16
17 of NAFLD? *Clin Sci.* 2017;131:2701-4.

18
19 (36) Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance.
20
21
22 *Cell Metab.* 2012;15:635-45.

23
24 (37) Baeck C, Wehr A, Karlmark KR, et al. Pharmacological inhibition of the chemokine CCL2
25
26
27 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury.
28
29
30 *Gut.* 2012;61:416-26.

31
32 (38) Tang ZL, Pham M, Hao YM, et al. Sex, Age, and BMI Modulate the Association of Physical
33
34
35 Examinations and Blood Biochemistry Parameters and NAFLD: A Retrospective Study on 1994
36
37
38 Cases Observed at Shuguang Hospital, China. *BioMed research international.* 2019.

39
40 (39) Liu M, Wang J, Zeng J, et al. Association of NAFLD With Diabetes and the Impact of BMI
41
42
43 Changes: A 5-Year Cohort Study Based on 18,507 Elderly. *J Clin Endocrinol Metab.*
44
45
46 2017;102:1309-16.

47
48 (40) Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease.
49
50
51 *N Engl J Med.* 2014;371:1131-41.

52
53 (41) Caprio S, Perry R, Kursawe R. Adolescent Obesity and Insulin Resistance: Roles of
54
55
56 Ectopic Fat Accumulation and Adipose Inflammation. *Gastroenterology.* 2017;152:1638-46.

57
58 (42) Taksali SE, Caprio S, Dziura J, et al. High visceral and low abdominal subcutaneous fat
59
60

1
2
3
4 stores in the obese adolescent: a determinant of an adverse metabolic phenotype. *Diabetes*.
5
6 2008;57:367-71.
7

8
9 (43) D'Adamo E, Cali AM, Weiss R, et al. Central role of fatty liver in the pathogenesis of insulin
10
11 resistance in obese adolescents. *Diabetes Care*. 2010;33:1817-22.
12

13
14 (44) Kursawe R, Dixit VD, Scherer PE, et al. A Role of the Inflammasome in the Low Storage
15
16 Capacity of the Abdominal Subcutaneous Adipose Tissue in Obese Adolescents. *Diabetes*.
17
18 2016;65:610-8.
19
20

21
22 (45) Stienstra R, van Diepen JA, Tack CJ, et al. Inflammasome is a central player in the
23
24 induction of obesity and insulin resistance. *P Natl Acad Sci USA*. 2011;108:15324-9.
25
26

27 (46) Yu Y, Cai J, She Z, et al. Insights into the Epidemiology, Pathogenesis, and Therapeutics
28
29 of Nonalcoholic Fatty Liver Diseases. *Adv Sci (Weinh)*. 2019;6:1801585.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1 Flow chart for participants exclusions performed

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3 Restricted cubic spline graph of risk of TyG index and the development of NAFLD.




Figure 3 Restricted cubic spline graph of risk of TyG index and the development of NAFLD.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4 The mediate effect of TyG index on WHtR and NAFLD.

Supplementary Table 1 relationship between TyG index and the risk of NAFLD
excluded subjects with diabetes, CVD and stroke

	TyG index			
	n	unadjusted	Model 1	Model 2
As continuous	37428	1.687(1.589,1.792)	1.571(1.480,1.668)	1.342(1.257,1.433)
Quartile 1	9536	Reference	Reference	Reference
Quartile 2	9368	1.036(0.938,1.144)	1.019 (0.923,1.125)	0.986(0.887,1.097)
Quartile 3	9350	1.239(1.127,1.362)	1.209(1.099,1.330)	1.076(0.970,1.193)
Quartile 4	9354	1.846(1.691,2.014)	1.681(1.540,1.836)	1.389(1.261,1.530)
<i>P</i> for trend		<0.001	<0.001	<0.001

Quartile 1 \leq 8.08; 8.09 < Quartile 2 \leq 8.40; 8.41 < Quartile 3 \leq 8.72; 8.73 < Quartile 4

Model 1: adjusted age and sex;

Model 2: model 1 plus living alone, current smoking, exercise, waist-to-height ratio, systolic blood pressure, diastolic blood pressure, alanine aminotransferase, aspartate aminotransferase, total bilirubin, total cholesterol.

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	1,2 2,3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3,4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4,5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	4,5 N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4,5
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4,5
Bias	9	Describe any efforts to address potential sources of bias	N/A
Study size	10	Explain how the study size was arrived at	4
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5,6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	5,6 N/A N/A N/A N/A
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	6,7 N/A 4
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	6,7 N/A 6
Outcome data	15*	Report numbers of outcome events or summary measures over time	6,7

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7-10
2			(b) Report category boundaries when continuous variables were categorized	7,8
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
4				
5	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	8,9
6				
7				
8				
9				
10				
11	Discussion			
12	Key results	18	Summarise key results with reference to study objectives	10
13	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12,13
14	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10,11,12
15	Generalisability	21	Discuss the generalisability (external validity) of the study results	13
16				
17	Other information			
18	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13
19				
20				
21				
22				
23				
24				
25				
26				
27				
28				
29				
30				
31				
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

Relationship between triglyceride glucose index and the incidence of nonalcoholic fatty liver disease in the elderly: a retrospective cohort study in China

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-039804.R3
Article Type:	Original research
Date Submitted by the Author:	15-Aug-2020
Complete List of Authors:	Chen, Huanan; Zhengzhou University, Department of Nutrition and Food Hygiene, College of Public Health Li, Sangsang; Xinyang Central Hospital, Medical record room Amoah, Adwoa Nyantakyiwaa ; Zhengzhou University, Department of Nutrition and Food Hygiene, College of Public Health Bo, Yacong; The Chinese University of Hong Kong, Jockey Club School of Public Health and Primary Care Chen, Xuejiao; Zhengzhou University, Department of Social Medicine, College of Public Health Shi, Zhan; Henan University of Traditional Chinese Medicine, Department of Pharmacy, Zhengzhou People's Hospital Wan, Guodong; Henan Province Health and Family Planning Commission, Health Commission of Xinzheng Huang, Jian; Henan Province Center for Disease Control and Prevention, Henan Province Center for Disease Control and Prevention shi, songhe; Zhengzhou University, Department of Epidemiology and Biostatistics Lyu, Qianjun ; Zhengzhou University, Department of Nutrition and Food Hygiene, College of Public Health; Zhengzhou University, Department of Nutrition, The First Affiliated Hospital of Zhengzhou University
Primary Subject Heading:	Gastroenterology and hepatology
Secondary Subject Heading:	Gastroenterology and hepatology
Keywords:	Hepatobiliary disease < GASTROENTEROLOGY, Lipid disorders < DIABETES & ENDOCRINOLOGY, PUBLIC HEALTH

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Relationship between triglyceride glucose index and the incidence of nonalcoholic fatty liver disease in the elderly: a retrospective cohort study in China

Chen Huanan¹, Li Sangsang², Amoah, Adwoa Nyantakyiwaa¹, Bo Yacong³, Chen Xuejiao⁴, Shi Zhan⁵, Wan Guodong⁶, Huang Jian⁷, Shi Songhe⁸, Lyu Qianjun^{1,9}.

1. Department of Nutrition and Food Hygiene, College of Public Health, Zhengzhou University, Zhengzhou, Henan, P.R. China.
2. Medical record room, Xinyang Central Hospital, Xinyang, Henan, P.R. China.
3. Jockey Club School of Public Health and Primary Care, the Chinese University of Hong Kong
4. Department of Social Medicine, College of Public Health, Zhengzhou University, Zhengzhou, Henan, P.R. China.
5. Department of Pharmacy, Zhengzhou People's Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, P.R. China.
6. Health Commission of Xinzheng, Henan Province Health and Family Planning Commission, Henan, P.R. China.
7. Central for Disease Control of Xinzheng, Henan Province Center for Disease Control and Prevention, Henan, P.R. China.
8. Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, P.R. China.
9. Department of Nutrition, The First Affiliated Hospital of Zhengzhou University, Henan, P.R. China

Corresponding Authors:

Qianjun Lyu, PhD, Department of Nutrition and Food Hygiene, College of Public Health, Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, 100 Science Road, Zhengzhou, China. Phone: (0371) 67781923, email: lqjnutr@zzu.edu.cn.

Songhe Shi, PhD, Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, 100 Science Road, Zhengzhou, China. Phone:(0371)

67781254, email: zzussh@126.com.

Abstracts

Objective: Nonalcoholic fatty liver disease (NAFLD) is one of the major causes of liver-related diseases but relationship between triglyceride glucose (TyG) and NAFLD in the elderly is not reported yet. In this study, we investigated the role of TyG index for predicting the incidence of NAFLD in the elderly.

Design and setting : This is a prospective cohort study in Henan, China, from 2011-2018.

Participants and Methods : In total, 46,693 elderly who participated in a routine physical examination programme from 2011 to 2018 were included in this study. TyG index was calculated as \ln [fasting triglyceride (mg/dl) \times fasting plasma glucose (mg/dl)/2], while NAFLD was defined as hepatic steatosis after excluding other causes based on the results of abdominal ultrasonography; Cox regression model was performed to explore the relationship between TyG index and NAFLD. Also, mediation effect was used to analyze the role of the TyG index in WHtR and NAFLD.

Results: During the 149041.50 person-years follow-up, a total of 5660 NAFLD events occurred (3.80/100 person-years). After adjusting for potential confounding factors, quartiles 4 of TyG index significantly increased the incidence of NAFLD compared with quartile 1, the hazard ratios (HRs) and 95% confidence intervals (CI) were 1.314(1.234,1.457). In addition, TyG index played a partial mediating role in the relationship between WHtR and NAFLD and indirect effect was 1.009(1.006,1.011).

Conclusion: Higher TyG index was associated with higher risk of NAFLD in the aged and therefore, TyG index may be a novel predictor for incidence of NAFLD. Further, regular examination and evaluation of the TyG index might be useful for controlling the occurrence of NAFLD.

Key words: Nonalcoholic fatty liver disease; Triglyceride glucose index; Waist-to-height ratio; Mediation effect.

Strengths and limitations of this study :

1
2
3
4 Data for this cohort study were retrieved from a large regular physical examination in
5 Henan, China.

6
7 Restricted cubic spline analysis and mediation effect were used in this study, which can
8 reflect the relationship between TyG index and NAFLD more realistically.

9
10 The sample size and statistical power were sufficient in this study.

11
12 The severity of disease in this cohort study was not available when data were retrieved.
13 Some participants were excluded in this study because they did not have abdominal
14 ultrasound testing.

15 16 17 18 19 **Introduction**

20
21 Nonalcoholic fatty liver disease(NAFLD) encompasses a series of spectrum of liver
22 diseases, ranging from simple steatosis, nonalcoholic steatohepatitis, cirrhosis to
23 hepatocellular carcinoma[1]. With the change of lifestyle and increase of obesity,
24 NAFLD currently exceeds viral hepatitis and is becoming the most common chronic
25 liver disease, affecting about a quarter of the common population in the world[2, 3].
26 NAFLD is one of the major causes of liver-related disease such as cirrhosis,
27 hepatocellular carcinoma and liver transplantation. Moreover, NAFLD is also
28 associated with higher prevalence and incidence of cardiovascular disease such as
29 coronary, cerebrovascular and peripheral vascular disease [4, 5]. In the next decade,
30 NAFLD is expected to become the leading cause for liver transplantation in the United
31 States instead of hepatitis C[6].

32
33
34
35
36
37
38
39
40
41
42
43
44
45 The development of NAFLD is a complex process involving genetic and environmental
46 factors. As an organ of metabolism, the disorder of glucose and lipid metabolism plays
47 an important role in the progress of NAFLD[7]. Several studies found that IR could
48 increase the risk of NAFLD even without the existence of T2DM and IR may be the
49 genesis of steatosis[7-10].Furthermore, as an early marker of IR, TyG has been
50 proposed to be an inexpensive and reliable surrogate to IR[11, 12] Yet researches about
51 the relationship between TyG index and the risk of NAFLD are limited [9, 13].
52 Additionally, as far as we know, the association between TyG index and the incidence
53
54
55
56
57
58
59
60

of NAFLD in the older has not been reported.

WHtR is a maker of abdominal obesity and studies have also reported that WHtR is related to IR[14, 15] and also the higher risk of NAFLD [16-22]. Whether there is an existing effect of TyG index on the relationship between WHtR and NAFLD and how it affects NAFLD is still unclear. This retrospective cohort study therefore sought to explore the relationship between baseline level of TyG index and the incidence of NAFLD.

1.Participants and methods

1.1 Subjects:

We retrospectively analyzed the 99,997 subjects who had the data of liver ultrasonography, fasting triglyceride as well as fasting plasma glucose in physical examination programme in Xinzheng, Henan Province, in Central China City from January 2011 to December 2018. This physical examination programme was for the local residents over 60 years old and was supported by the government of Xinzheng, Henan Province in China. Individuals with any of the following criteria were excluded:1) missing follow-up; 2) subjects with NAFLD at baseline;3) subjects with hepatitis B or C virus or had the history of excess alcohol intake (the threshold for women <20 g/d and <30 g/d for men). A total of 46,693 eligible participants were included in this cohort study (**Figure 1**). The datasets generated and/or analyzed during the current study are available upon request. Given the retrospective nature of the research, the requirement for informed consent was waived. Patients were not involved in the recruitment and conduct of the study. The study protocol was approved by ethics committee of Zhengzhou University in China (Approve number: ZZURIB202004).

Figure 1 Flow chart for participants exclusions performed

1.2 Data collection

Demographic data and clinical information of the subjects were collected when they underwent health check-up. Demographic data included age, sex, excess alcohol intake

(yes/no), current smoking status (yes/no), lives alone(yes/no) and exercises regularly(yes/no). The definition of current smoking was that subjects used to smoke 100 cigarettes or above in their lifetime, and now is still smoking regularly. Excessive drinking was defined as drinking more than 30g /d for men and 20g/d for women. Exercising regularly was defined as more than 3 times a week, and 30 minutes moderate intensity exercise each time. The clinic records included anthropometric measurements (such as height, weight, blood pressure, waist circumference) and laboratory data. Height measurement required the subjects without shoes, stand straight on the ground, and their hips and heels against the wall, to measure the weight, the participants were without shoes and wore light clothing. Blood pressure of the subjects in a sitting position after 5 minutes of rest was measured twice by an electronic sphygmomanometer (Omron HEM-7125, Kyoto, Japan), and the mean value of the two measurements was recorded. Waist circumference was measured at the midpoint of the distance between the lowest costal ridge and the upper border of the iliac crest. After fasting for 8 hours, the blood samples of subjects were collected to determine the level of fasting plasma glucose (FPG), total cholesterol (TC) and triglyceride (TG) using a biochemical detector (DIRUI CS380, Changchun, China). Alanine aminotransferase (ALT), aspartate transaminase (AST) and total bilirubin (TB) was detected by (DIRUI CS380, Changchun, China). The TyG index were calculated as the \ln [fasting TG (mg/dl) \times FPG (mg/dl)/2]. WHtR was defined as waist circumference(cm)/height(cm).

1.3 NAFLD definition

All participants of this study underwent liver ultrasonography (SIUI CZXL-38G, Shantou, China). The results of ultrasound prompted the existence of steatohepatitis: enhanced liver echogenicity, echogenicity greater in liver than kidneys, deep attenuation and vascular blurring[23] and after excluding the steatohepatitis caused by alcohol, viruses and drugs was defined as NAFLD. All ultrasound examinations were performed by an experienced professional radiologist.

1.4 Statistics

Categorical variables were showed as proportions while continuous variables were

presented as means \pm standard deviation (SD) or median (interquartile range) (IQR). ANOVA/two - paired sample t tests (continuous variables, normal distribution) and chi-square tests (categorical variables) were used to compare the difference in different groups. Logistic regression for categorical variables and linear regression for continuous variables were used to obtain the *P* value for trend.

Cox regression models were used to explore the relationship between TyG index and the incidence of NAFLD, the lowest quartiles of TyG index was defined as the reference. Hazards ratio (*HR*) and confidence interval (*CI*) of NAFLD in quartiles and continuous were expressed in separate models. To assess the relationship across increasing quartiles, *P* value for trend tests were used by entering median value in each quartile in Cox regression models.

AUCs were used to evaluate the ability of the baseline TyG index to predict the risk of NAFLD. Restricted cubic spline models were used to explore whether there was a nonlinear relationship between continuous and occurrence of NAFLD [24]. Mediation analysis used a Cox regression to study the mediate effect of TyG index between WHtR and NAFLD.

Mediation analysis was conducted using R version 3.5.0 (R Foundation for Statistical Computing, Vienna, Austria), and Restricted cubic spline were performed in Stata v 12.0 (Stata Corp, College Station, TX, USA). The other analyses were performed by SPSS software, version 21.0 (SPSS Inc, Chicago). Probability values for statistical tests, where two-tailed *P*-values < 0.05 were regarded as significant.

2. Result

2.1 Baseline Characteristics of included subjects

A total of 46,693 subjects were included in this study. The baseline characteristics of included participants based on follow-up were presented in **Table 1**. The mean age of subjects was 68.91 (7.17) and 48.89% were men. The average follow-up was 3.19(1.52) years, during the 149041 person-years follow-up, 5660 subjects occurred NAFLD (3.80/100 person-years). Subjects with NAFLD with higher BMI, WHtR, TC, FBG, DBP, SBP, ALT, and TB and the incidence of NAFLD was higher in younger, current

smoking, regular exercise, with diabetes and hypertension but the baseline level of AST had no association with the incidence of NAFLD.

Table 1 baseline characteristics of included subjects according to the follow-up outcome

variables	No NAFLD (n=41033)	NAFLD (n=5660)	P value
Men, n (%) †	20799(50.69)	2033(35.92)	<0.001
Age (years) ‡	69.18±7.27	66.93±6.00	<0.001
Current smoking, n (%) †	6846 (16.70)	594(10.51)	<0.001
Exercise, n (%) †	7865(19.22)	1131(20.02)	<0.001
Live alone, n (%) †	8772(21.38)	1015(17.93)	<0.001
Diabetes, n (%) †	5554(13.54)	1344(23.75)	<0.001
Hypertension, n (%) †	15945 (38.86)	2952(52.16)	<0.001
WHR‡	0.51±0.06	0.54±0.07	<0.001
BMI‡	23.62±2.85	26.02±3.10	<0.001
SBP (mmHg) ‡	132.62±19.38	135.32±19.76	<0.001
DBP (mmHg) ‡	78.92±10.34	80.91±10.33	<0.001
FPG (mmol/L) §	5.20(4.70-5.70)	5.30(4.80-5.93)	<0.001
TC (mmol/L) §	4.59(4.01-5.21)	4.69(4.09-5.38)	<0.001
TG (mmol/L) §	1.10(0.81-1.47)	1.28(0.90-1.77)	<0.001
TB (µmol/L) §	11.51(8.60-14.10)	11.30(8.30-13.80)	<0.001
ALT(U/L) §	18.00(13.00-24.50)	18.60(14.00-25.00)	<0.001
AST(U/L) §	21.80(16.89-26.90)	21.90(16.89-27.00)	0.892
TyG‡	8.43±0.54	8.61±0.59	<0.001

†: n (%); ‡: mean (SD); §: median (IQR)

Abbreviations: BMI, body mass index; WHtR, waist-to-height ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; TC, triglycerides; TG, triglyceride; TB, total bilirubin; ALT, alanine aminotransferase, AST, aspartate aminotransferase; TyG, triglyceride glucose.

2.2 Association between TyG index and NAFLD

The relationship between TyG index and the incidence of NAFLD were showed in **Table 2**. Compared with quartile 1 of TyG index, the hazard ratio (HR) and its corresponding 95% confidence interval (CI) for quartile2, quartile3, and quartile 4 were 1.056(0.971,1.149), 1.300(1.200,1.408) and 1.972(1.832,2.123), respectively. Risk for NAFLD was significantly higher with increasing quartiles of TyG for the *P* value of trend of linearity <0.001. In addition, even after adjusted possible confounding factors, the risk of quartile 3 of TyG index (1.314(1.234,1.457)) on the incidence of NAFLD still existed. In order to further verify the relationship between the TyG index and the

incidence of NAFLD, TyG index was used as continuous variables for the above analysis and the results also proved that higher level of TyG increased the risk of NAFLD (1.265(1.200,1.334)), even after adjusted possible confounding factors. These results proved that the baseline level of TyG was associated with the risk of NAFLD, thus the higher the TyG level, the higher incidence of NAFLD.

Since the majority of the subjects could not respond on their history of lipid-lowering therapy or antidiabetic drugs, we failed to access information about therapy. Sensitivity analysis (n=37428) was executed after excluding subjects with diabetes, CVD and stroke, who might take medicine that affects level of FPG and TG. The results of sensitivity analysis (Suppl table 1) also suggested that higher level of TyG significantly increased the incidence of NAFLD, which were similar with the findings in total population.

Table 2 relationship between TyG index and the risk of NAFLD

	N	TyG index		
		unadjusted	Model 1	Model 2
As continuous	50037	1.697(1.619,1.779)	1.577(1.504,1.653)	1.265(1.200,1.334)
Quartile 1	12556	Reference	Reference	Reference
Quartile 2	12458	1.056(0.971,1.149)	1.035 (0.951,1.126)	0.980(0.895,1.073)
Quartile 3	12522	1.300(1.200,1.408)	1.259(1.162,1.364)	1.090(0.999,1.190)
Quartile 4	12501	1.972(1.832,2.123)	1.783(1.655,1.920)	1.314(1.234,1.457)
<i>P</i> for trend		<0.001	<0.001	<0.001

Quartile 1≤8.11; 8.12<Quartile 2≤8.44; 8.45<Quartile 3≤8.78; 8.79<Quartile 4

Model 1: adjusted age and sex;

Model 2: model 1 plus living alone, current smoking, exercise, waist-to-height ratio, systolic blood pressure, diastolic blood pressure, alanine aminotransferase, aspartate aminotransferase, total bilirubin, total cholesterol and diabetes.

2.3 The ability of TyG to predict NAFLD

The receiver operating characteristic curves (ROC) were used to evaluate the ability of baseline level of TyG to predict the development of NAFLD. The best cutoff value for TyG index to diagnosis NAFLD was 8.63, and its corresponding area under the receiver operating characteristic curves (AUCs) was 0.60 (95%CI:0.58,0.61), showed in **Figure 2A**. Subgroup analysis was performed to further analyze the influence of sex on ability

of TyG index to predict incident NAFLD, the best cutoff value for men (8.68) was lower in men than women (8.75), and corresponding AUCs was 0.587 (95%CI:0.573-0.600) for men and 0.584 (95%CI:0.573-0.594) for men, respectively(**Figure 2B and 2C**).

Figure 2 ROC curve of TyG on NAFLD

Receiver operating characteristics (ROC) curves for baseline TyG to predict incident NAFLD among 60 years old or older. TyG, triglyceride glucose; NAFLD, nonalcoholic fatty liver diseases.

2.4 Restricted cubic spline analysis to evaluate the relationship between TyG and NAFLD

In order to further explore the relationship between TyG and the risk of NAFLD, restricted cubic spline graph was used to analyze the dose-response relationship between TyG and the incidence of NAFLD. As shown in **Figure 3A**, there was a nonlinear relationship between level of TyG index and the risk of NAFLD based on the adjusted Cox regression model. This result proved again that higher level of TyG was associated with higher incidence of NAFLD. Subgroup analyses also found that there was a nonlinear relationship between TyG index and incident NAFLD both in men and women (**Figure 3B and C**).

Figure 3 Restricted cubic spline graph of risk of TyG index and the development of NAFLD.

Multivariate adjusted hazard ratios of NAFLD increased during follow-up when the baseline level of TyG index was 8.63 and above. Adjusted variables including age, sex (not for sex subgroup analysis), living alone, current smoking, exercise, waist-to-height ratio, systolic blood pressure, diastolic blood pressure, alanine aminotransferase, aspartate aminotransferase, total bilirubin, total cholesterol. TyG, triglyceride glucose; NAFLD, nonalcoholic fatty liver diseases; CI, confidence interval.

2.5 Mediation effects

In previous analysis we found that WHtR was associated with the incidence of NAFLD, what's more, WHtR was also associated with TyG index ($P < 0.05$, and the data wasn't

shown). If WHtR would lead to IR and TyG index was a reliable and cheap surrogate indicate for IR, then there might be a mediating effect of TyG index between WHtR and NAFLD. Therefore, mediation analysis was used to confirm whether there was a mediating effect and to what extent TyG index affect the relationship between WHtR and NAFLD. Results (presented in **Table 3 and Figure 4**) of mediation analysis revealed that the total effect of WHtR on NAFLD was 1.476 (1.437,1.517) and the direct effect was 1.463(1.842,1.950). Therefore, TyG index played a partial role and the indirect effect was 1.019 (1.006,1.011). This result may indicate that abdominal obesity may lead to disorders of glycolipid dyslipidemia which can lead to an increase of the TyG index.

Table 3 Mediation analysis of the relationship between TyG index and NAFLD by WHtR

Effect	HR (95%CI)
Total effect	1.476 (1.437,1.517)
Direct effect	1.463 (1.842,1.950)
Indirect effect	1.009(1.006,1.011)

Figure 4 The mediate effect of TyG index on WHtR and NAFLD.

The effect of WHtR on NAFLD was mediated by baseline level TyG index by adjusted potential confounders namely age, sex, living alone, current smoking, exercise, systolic blood pressure, diastolic blood pressure, alanine aminotransferase, aspartate aminotransferase, total bilirubin, total cholesterol.

3. Discussion

With the acceleration of the aging process, the health in the elderly has gradually become an important issue in the society. NAFLD, a common liver disease in China, also has become one of the main health problems of the elderly. Although there were some studies about TyG index and NAFLD, research about TyG index and the incidence of NAFLD in the older adults has not been reported.

In this retrospective cohort study, we found the incidence of NAFLD was 3.80/100 person-years among the elderly over 60, which was lower than a cohort study of Korea

1
2
3
4 (the incidence of NAFLD was 4.84/100 person-years)[25]. Probably, the age of the
5 subjects in the Korean cohort study(mean age was 36.1) was younger than ours and age
6 could affect the prevalence and severity of NAFLD[26]. Additionally, the incidence of
7 NAFLD decreased as the age increased in this study and the $P_{\text{value for trend}} < 0.001$ (data
8 not presented in this research). A retrospective cohort study on TyG index and NAFLD
9 in Japan also found that higher TyG was associated with higher risk of NAFLD, which
10 was consistent with our results[13]. As far as we know, this research is the first study
11 to focus on the effect of TyG index on the incidence of NAFLD in the elderly in China.
12 Our study also reported the relationship between TyG index was nonlinear hence the
13 incidence of NAFLD would increase significantly when TyG is above 8.63.
14 Furthermore, the results of the mediation effect suggested that TyG index was not an
15 independent factor for the development of NAFLD, but a partial mediator between
16 WHtR and NAFLD.
17

18
19 The results of ROC suggested that 8.63 was the best cutoff value of TyG index for
20 predicting the incidence of NAFLD. While, the cut off value TyG index was higher
21 than Simental-Mendía LE et.al[27],which might be caused by the following reasons.
22 Firstly, the participants were different between two studies, in Simental-Mendía LE
23 et.al research, the participants were from asymptomatic women aged 20 to 65 years in
24 Mexico, while in our study, the participants were 60 or older from China (including
25 men and women), moreover, the cutoff value in our research was similar to several
26 studies from Asia[13, 28, 29]; Secondly, study design of Simental-Mendía LE et.al is
27 different from ours; What's more, the methods to diagnosis NAFLD were different;
28 Additionally, the mean values of TyG index were different. The above might be the
29 reasons that resulted in different cutoff value. TyG index is an inexpensive and reliable
30 surrogate index for IR and plays an important role in the development and progression
31 of NAFLD. Consequently, even in the absence of diabetes, IR can lead to changes from
32 normal liver to NAFL to NASH[10]. Various studies have confirmed that IR is closely
33 related to the occurrence and development of NAFLD[30-33].
34

35
36 The mechanism of IR on NAFLD could be explained by the following reasons. On one
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 hand, IR has a direct effect on metabolism of glucose and lipid, and thus participates in
5 the incidence and development of NAFLD[30]. Insulin resistance reduces glucose
6 uptake in the adipose tissues and muscles, and reduces the hydrolysis of triglycerides
7 in adipose tissue. Meanwhile, High insulin levels can increase the uptake of free fatty
8 acids in the liver and the synthesis of TG, causing excessive accumulation of fat in the
9 liver, which could initiate steatosis and then lead to the occurrence of NAFLD [7, 34,
10 35]. On the other hand, IR is always linked to chronic mild inflammation caused by the
11 release of inflammatory factors, such as $TNF\alpha$, IL-6, IL-1 and monocyte chemotactic
12 protein-1, which can in turn promote IR and participate in the development and
13 progression of NAFLD[36, 37].

14
15
16
17
18
19
20
21
22
23 Obesity is a key factor in development and progression of NAFLD. It has been
24 documented that BMI is associated with incidence of NAFLD[38, 39]. While growing
25 evidences suggested that the determinant of IR is not the degree of obesity, but the
26 distribution of fat [40-43]. Central obesity can lead to inflammatory, oxidative stress
27 and metabolic disorders, which are related to the development of IR[44, 45]. In this
28 study, WHtR, an indicator of central obesity, was associated with NAFLD and the
29 effect was mediated by TyG index among the study participants. This could be that
30 central obesity leads to an increase in the TyG index and thus results in NAFLD.

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The major strength of this study was a large sample size retrospective cohort study
which included 46,693 aged more than 60 years old. it is believed a cohort study could
better reflect the real relationship between TyG index and NAFLD. Moreover, we
established a nonlinear relationship between TyG index and NAFLD using cubic spline
graph analysis, furthermore, TyG index played a mediation effect between WHtR and
NAFLD in this study. However, there were several limitations in this study. First, liver
biopsy is gold standard to diagnosis NAFLD, while, in this study, we executed
abdominal ultrasound to diagnosis NAFLD. While, liver biopsy is unrealistic to screen
NAFLD in general population for the prevalence of NAFLD is high. Previous study
also found that abdominal ultrasound is less expensive than other advanced imaging
methods, and is currently the most widely used imaging tool in clinic and the most

1
2
3
4 acceptable method for the first-line screening of steatosis[46]. Furthermore, the subjects
5 could not provide their history of lipid-lowering therapy or antidiabetic drugs as they
6 were elder therefore, information about therapy was missing in the data. Additionally,
7 we could not evaluate the relationship between TyG index and different NAFLD
8 severity. Also, we lacked other more accurately index which can reflect the abdominal
9 obesity status. Even though we used WHtR to indicate the abdominal obesity, we were
10 unable to assess a more accurately visceral fat index and the prevalence of NAFLD.

11
12
13
14
15
16
17 In conclusion, high baseline level of TyG index is significantly associated with a higher
18 risk of NAFLD. In addition, TyG index plays a partial mediating role in the relationship
19 between WHtR and NAFLD. Our results suggest that it has important clinical meanings
20 for monitoring TyG index to prevent NAFLD.
21
22

23 24 25 **Acknowledgements:**

26
27 This research was funded by the National Natural Science Foundation of China (Grant
28 No. 81673165), the National Key Research and Development Programme of China
29 (Grant Nos 2017YFC1307705 and 2016YFC0106907). In addition, the authors are
30 grateful to Junxing Fan for helping with the quality control of the data. The funders had
31 no role in the study design, data collection and analysis, decision to publish, or
32 preparation of the manuscript.
33
34
35
36
37
38

39 40 **Author Contributions:**

41
42 H.C. and Q.L. designed the study. H.C., S.L., B.Y., X.C., Z.S., W.G and J.H.
43 participated in the data collection and analysis. H.C. and A.A. drafted this manuscript,
44 H.C. S.L. and S.S. interpreted the data. S.S and Q.L. reviewed and revised this
45 manuscript. All authors approved the final manuscript.
46
47
48
49

50 51 **Financial support:**

52
53 This research was funded by the National Natural Science Foundation of China (Grant
54 No. 81673165), the National Key Research and Development Programme of China
55 (Grant Nos 2017YFC1307705 and 2016YFC0106907)
56
57
58
59
60

Conflict of Interest:

All authors have no conflicts of interest.

Patient and public involvement: Participants were not involved in the recruitment and conduct of the study

Patient consent for publication: Given the retrospective nature of the research, the requirement for informed consent was waived. Patients were not involved in the recruitment and conduct of the study. The study protocol was approved by ethics committee of Zhengzhou University in China.

Ethics approval:

The study protocol was approved by ethics committee of Zhengzhou University in China (approval number: ZZURIB202004). Given the retrospective nature of the research, the requirement for informed consent was waived.

Provenance and peer review: Not commissioned; externally peer reviewed

Data availability statement: The datasets generated and/or analyzed during the current study are available upon request.

Open access: This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

References

- (1) Finck BN. Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis. *Diabetes*. 2018;67:2485-93.
- (2) Yu Y, Cai JJ, She ZG, et al. Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases. *Adv Sci*. 2019;6.

- 1
2
3
4 (3) Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in
5
6 Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology*. 2019;156:1264-81 e4.
7
8
9 (4) Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular
10
11 disease or cirrhosis. *Nat Rev Gastroenterol Hepatol*. 2013;10:330-44.
12
13
14 (5) Schindhelm RK, Heine RJ, Diamant M. Prevalence of nonalcoholic fatty liver disease and
15
16 its association with cardiovascular disease among type 2 diabetic patients. *Diabetes Care*.
17
18 2007;30:e94; author reply e5.
19
20
21 (6) Goldberg D, Ditah IC, Saeian K, et al. Changes in the Prevalence of Hepatitis C Virus
22
23 Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With
24
25 Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. *Gastroenterology*.
26
27 2017;152:1090-+.
28
29
30
31 (7) Watt MJ, Miotto PM, De Nardo W, et al. The liver as an endocrine organ - linking NAFLD
32
33 and insulin resistance. *Endocr Rev*. 2019.
34
35
36
37 (8) Baratta F, Pastori D, Polimeni L, et al. Adherence to Mediterranean Diet and Non-Alcoholic
38
39 Fatty Liver Disease: Effect on Insulin Resistance. *American Journal of Gastroenterology*.
40
41 2017;112:1832-9.
42
43
44
45 (9) Fedchuk L, Nascimbeni F, Pais R, et al. Performance and limitations of steatosis biomarkers
46
47 in patients with nonalcoholic fatty liver disease. *Alimentary Pharmacology & Therapeutics*.
48
49 2014;40:1209-22.
50
51
52
53 (10) Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. *Nat*
54
55 *Rev Gastro Hepat*. 2019;16:377-86.
56
57
58 (11) Du T, Yuan G, Zhang M, et al. Clinical usefulness of lipid ratios, visceral adiposity indicators,
59
60

1
2
3
4 and the triglycerides and glucose index as risk markers of insulin resistance. Cardiovasc
5
6 Diabetol. 2014;13:146.
7

8
9 (12) Nor NSM, Lee S, Bacha F, et al. Triglyceride glucose index as a surrogate measure of
10
11 insulin sensitivity in obese adolescents with normoglycemia, prediabetes, and type 2 diabetes
12
13 mellitus: comparison with the hyperinsulinemic-euglycemic clamp. Pediatr Diabetes.
14
15 2016;17:458-65.
16
17

18
19 (13) Kitae A, Hashimoto Y, Hamaguchi M, et al. The Triglyceride and Glucose Index Is a
20
21 Predictor of Incident Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. Can
22
23 J Gastroenterol Hepatol. 2019;2019:5121574.
24
25

26
27 (14) Khoury M, Manlhiot C, McCrindle BW. Role of the Waist/Height Ratio in the
28
29 Cardiometabolic Risk Assessment of Children Classified by Body Mass Index. J Am Coll
30
31 Cardiol. 2013;62:742-51.
32
33

34
35 (15) Xi B, Mi J, Zhao M, et al. Trends in abdominal obesity among U.S. children and adolescents.
36
37 Pediatrics. 2014;134:e334-9.
38
39

40
41 (16) Huang X, Wang QY, Liu TT, et al. Body fat indices as effective predictors of insulin
42
43 resistance in obese/non-obese polycystic ovary syndrome women in the Southwest of China.
44
45 Endocrine. 2019;65:81-5.
46
47

48
49 (17) Motamed N, Rabiee B, Hemasi GR, et al. Body Roundness Index and Waist-to-Height
50
51 Ratio are Strongly Associated With Non-Alcoholic Fatty Liver Disease: A Population-Based
52
53 Study. Hepat Mon. 2016;16:e39575.
54
55

56
57 (18) Zheng RD, Chen ZR, Chen JN, et al. Role of Body Mass Index, Waist-to-Height and Waist-
58
59 to-Hip Ratio in Prediction of Nonalcoholic Fatty Liver Disease. Gastroenterol Res Pract.
60

1
2
3
4 2012;2012:362147.
5

6 (19) Zhang X, Wan Y, Zhang S, et al. Nonalcoholic fatty liver disease prevalence in urban
7
8 school-aged children and adolescents from the Yangtze River delta region: a cross-sectional
9
10 study. *Asia Pac J Clin Nutr.* 2015;24:281-8.
11
12

13 (20) Ramirez-Velez R, Izquierdo M, Correa-Bautista JE, et al. Grip Strength Moderates the
14
15 Association between Anthropometric and Body Composition Indicators and Liver Fat in Youth
16
17 with an Excess of Adiposity. *J Clin Med.* 2018;7.
18
19

20 (21) Lin MS, Lin TH, Guo SE, et al. Waist-to-height ratio is a useful index for nonalcoholic fatty
21
22 liver disease in children and adolescents: a secondary data analysis. *Bmc Public Health.*
23
24 2017;17.
25
26

27 (22) Procino F, Misciagna G, Veronese N, et al. Reducing NAFLD-screening time: A
28
29 comparative study of eight diagnostic methods offering an alternative to ultrasound scans. *Liver*
30
31 *Int.* 2019;39:187-96.
32
33

34 (23) Kojima S, Watanabe N, Numata M, et al. Increase in the prevalence of fatty liver in Japan
35
36 over the past 12 years: analysis of clinical background. *J Gastroenterol.* 2003;38:954-61.
37
38

39 (24) Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in
40
41 public health research. *Stat Med.* 2010;29:1037-57.
42
43

44 (25) Jang EH, Chang Y, Ryu S, et al. Cardiovascular Health Metrics in the Development and
45
46 Regression of Nonalcoholic Fatty Liver Disease: A Cohort Study. *J Clin Med.* 2019;8.
47
48

49 (26) Petta S, Eslam M, Valenti L, et al. Metabolic syndrome and severity of fibrosis in
50
51 nonalcoholic fatty liver disease: An age-dependent risk profiling study. *Liver Int.* 2017;37:1389-
52
53 96.
54
55
56
57
58
59
60

1
2
3
4 (27) Simental-Mendia LE, Simental-Mendia E, Rodriguez-Hernandez H, et al. The product of
5
6 triglycerides and glucose as biomarker for screening simple steatosis and NASH in
7
8 asymptomatic women. *Ann Hepatol.* 2016;15:715-20.

9
10
11 (28) Zheng R, Du Z, Wang M, et al. A longitudinal epidemiological study on the triglyceride and
12
13 glucose index and the incident nonalcoholic fatty liver disease. *Lipids Health Dis.* 2018;17:262.

14
15
16 (29) Zhang S, Du T, Zhang J, et al. The triglyceride and glucose index (TyG) is an effective
17
18 biomarker to identify nonalcoholic fatty liver disease. *Lipids Health Dis.* 2017;16:15.

19
20
21 (30) Khan RS, Bril F, Cusi K, et al. Modulation of Insulin Resistance in Nonalcoholic Fatty Liver
22
23 Disease. *Hepatology (Baltimore, Md).* 2018.

24
25
26 (31) Sung KC, Lee MY, Lee JY, et al. Natural course of fatty liver in 36,195 South Korean adults.
27
28 *Scientific reports.* 2019;9:9062.

29
30
31 (32) Ballestri S, Nascimbeni F, Romagnoli D, et al. Type 2 Diabetes in Non-Alcoholic Fatty Liver
32
33 Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight. *Int J Mol Sci.*
34
35 2016;17:355.

36
37
38 (33) Sookoian S, Pirola CJ. Systematic review with meta-analysis: risk factors for non-alcoholic
39
40 fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean
41
42 and obese patients. *Aliment Pharmacol Ther.* 2017;46:85-95.

43
44
45 (34) Wong VWS, Chan WK, Chitturi S, et al. Asia-Pacific Working Party on Non-alcoholic Fatty
46
47 Liver Disease guidelines 2017Part 1: Definition, risk factors and assessment. *J Gastroen*
48
49 *Hepatol.* 2018;33:70-85.

50
51
52 (35) Gastaldelli A. Insulin resistance and reduced metabolic flexibility: cause or consequence
53
54 of NAFLD? *Clin Sci.* 2017;131:2701-4.

- 1
2
3
4 (36) Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance.
5
6 Cell Metab. 2012;15:635-45.
7
8
9 (37) Baeck C, Wehr A, Karlmark KR, et al. Pharmacological inhibition of the chemokine CCL2
10
11 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury.
12
13 Gut. 2012;61:416-26.
14
15
16 (38) Tang ZL, Pham M, Hao YM, et al. Sex, Age, and BMI Modulate the Association of Physical
17
18 Examinations and Blood Biochemistry Parameters and NAFLD: A Retrospective Study on 1994
19
20 Cases Observed at Shuguang Hospital, China. BioMed research international. 2019.
21
22
23 (39) Liu M, Wang J, Zeng J, et al. Association of NAFLD With Diabetes and the Impact of BMI
24
25 Changes: A 5-Year Cohort Study Based on 18,507 Elderly. J Clin Endocrinol Metab.
26
27 2017;102:1309-16.
28
29
30 (40) Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease.
31
32 N Engl J Med. 2014;371:1131-41.
33
34
35 (41) Caprio S, Perry R, Kursawe R. Adolescent Obesity and Insulin Resistance: Roles of
36
37 Ectopic Fat Accumulation and Adipose Inflammation. Gastroenterology. 2017;152:1638-46.
38
39
40 (42) Taksali SE, Caprio S, Dziura J, et al. High visceral and low abdominal subcutaneous fat
41
42 stores in the obese adolescent: a determinant of an adverse metabolic phenotype. Diabetes.
43
44 2008;57:367-71.
45
46
47 (43) D'Adamo E, Cali AM, Weiss R, et al. Central role of fatty liver in the pathogenesis of insulin
48
49 resistance in obese adolescents. Diabetes Care. 2010;33:1817-22.
50
51
52 (44) Kursawe R, Dixit VD, Scherer PE, et al. A Role of the Inflammasome in the Low Storage
53
54 Capacity of the Abdominal Subcutaneous Adipose Tissue in Obese Adolescents. Diabetes.
55
56
57
58
59
60

1
2
3
4 2016;65:610-8.
5

6 (45) Stienstra R, van Diepen JA, Tack CJ, et al. Inflammasome is a central player in the
7
8 induction of obesity and insulin resistance. P Natl Acad Sci USA. 2011;108:15324-9.
9
10

11 (46) Yu Y, Cai J, She Z, et al. Insights into the Epidemiology, Pathogenesis, and Therapeutics
12
13 of Nonalcoholic Fatty Liver Diseases. Adv Sci (Weinh). 2019;6:1801585.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Figure 1 Flow chart for participants exclusions performed

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2 ROC curve of TyG on NAFLD




Figure 3 Restricted cubic spline graph of risk of TyG index and the development of NAFLD.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4 The mediate effect of TyG index on WHtR and NAFLD.

Supplementary Table 1 relationship between TyG index and the risk of NAFLD
excluded subjects with diabetes, CVD and stroke

	TyG index			
	n	unadjusted	Model 1	Model 2
As continuous	37428	1.687(1.589,1.792)	1.571(1.480,1.668)	1.342(1.257,1.433)
Quartile 1	9536	Reference	Reference	Reference
Quartile 2	9368	1.036(0.938,1.144)	1.019 (0.923,1.125)	0.986(0.887,1.097)
Quartile 3	9350	1.239(1.127,1.362)	1.209(1.099,1.330)	1.076(0.970,1.193)
Quartile 4	9354	1.846(1.691,2.014)	1.681(1.540,1.836)	1.389(1.261,1.530)
<i>P</i> for trend		<0.001	<0.001	<0.001

Quartile 1 \leq 8.08; 8.09 < Quartile 2 \leq 8.40; 8.41 < Quartile 3 \leq 8.72; 8.73 < Quartile 4

Model 1: adjusted age and sex;

Model 2: model 1 plus living alone, current smoking, exercise, waist-to-height ratio, systolic blood pressure, diastolic blood pressure, alanine aminotransferase, aspartate aminotransferase, total bilirubin, total cholesterol.

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	1,2 2,3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3,4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4,5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	4,5 N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4,5
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4,5
Bias	9	Describe any efforts to address potential sources of bias	N/A
Study size	10	Explain how the study size was arrived at	4
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5,6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	5,6 N/A N/A N/A N/A
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	6,7 N/A 4
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	6,7 N/A 6
Outcome data	15*	Report numbers of outcome events or summary measures over time	6,7

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7-10
2			(b) Report category boundaries when continuous variables were categorized	7,8
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
4				
5	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	8,9
6				
7				
8				
9				
10				
11	Discussion			
12	Key results	18	Summarise key results with reference to study objectives	10
13	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12,13
14	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10,11,12
15	Generalisability	21	Discuss the generalisability (external validity) of the study results	13
16				
17	Other information			
18	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13
19				
20				
21				
22				
23				
24				
25				
26				
27				
28				
29				
30				
31				
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.